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Abstract 
The effectiveness of adoptive immunotherapy of cancer using LAI< cells 
and IL-2 depends on the accumulation of transferred effector cells at the 
tumour sites. In vitro LAK cell have been demonstrated to have broad 
cytotoxic activity to a wide variety of tumour cells in a non-major-
histocompatibility complex-restricted manner, and independent of the 
presence of tumour specific antigens. LAK cells have now been used 
effectively in a small number of human trials. The effective delivery of 
these cells to the tumour site in vivo is one of the main aspects of this type 
of immunotherapy that requires further investigation. Conventional 
systemic infusion has shown a limited migration pattern of LAK cells. In 
this study the degree of entrapment of LAK cells in organs following local 
infusion has been determined. The large size and rigidity of LAK cells 
may be one mechanism which restricts the distribution of these cells. In 
addition, in this study the effect of mannitol, a hyperosmotic agent which 
increases the space between vascular endothelial cells, on the uptake of 
intraportal LAI< cells into liver has been determined. 
A-LAK cells are obtained by culture of N.W.P. lymphocytes with IL-2. In 
this study A-LAK cells were characterised by typical morphologic 
appearance, cell surface phenotype, and cytotoxic specificity. Purified A-
LAI< cells were morphologically large granular lymphocytes, 67%-90% of 
which showed the surface marker phenotype of NK/LGL cells (OXs). The 
population contained few pan-T cells (only 4.0-6.5% of cells expressing 
OX19). No B cell surface marker lg was detectable in the A-LAK cell 
population. These cells showed high ability to lyse YAC-1 and P-815 
cultured tumour target cells in 4h 51Cr-release cytotoxic assays. At an 
Effector:Target ratio of 40:1 A-LAK cells lysed 70% P815 and 100% YAC-1 
cells. 
After labelling A-LAK cells with 51Cr, the effect of intraportal infussion of 
30% mannitol on the distribution of intraportally infused A-LAK cells in 
liver was studied. The trafficking studies were carried out in three 
groups. In Group 1, 51Cr labelled A-LAK cells were systemically infused 
through the tail vein of rats as a control group. In Group 2 and Group 3, 
A-LAK cells were infused into syngeneic rats through the portal vein 
without or following prior portal infusion of 30% mannitol. Two hours 
after LAK cell administration the rats were sacrificed and the radioactivity 
in liver, lung, spleen, blood, MLN, kidney and brain were measured to 
determine the distribution of A-LAK cells to these organs. 
The results showed that intraportal mannitol was associated with an 
increased percentage of LAK cells in the liver compared with regionally 
infused LAK cells without mannitol (54% vs 24%; P<0.0005). The 
administration of intraportal mannitol was also associated with increased 
distribution of A-LAK cells into the brain (0.26% vs 0.08%; P<0.05) and 
MLN (0.05% vs 0.02%; P<0.05). There was no significant increase in 
uptake of A-LAK cells in lung (8.39% vs 6.01 %), spleen (1.00% vs 0.98%), 
or kidney (1.44% vs 1.78%) following intraportal mannitol. 
There was no significant increase of the A-LAK cell distribution to the 
liver by regional infusion without mannitol (24% vs 16%). Systemic 
injection gave greater A-LAK uptake into lungs (15.65%) than portal 
injection {6.05%, P=0.05). There was no significant differences of cell 
distribution in spleen, MLN, kidney and brain by these two routes of 
infusion. 
These results showed that mannitol has the effect of increasing the 
distribution of LAK cells into the liver. Augmentation of LAK cell 
accumulation in the liver may help to enhance the tumouricidal activity of 
these cells to hepatic metastases. The results of this thesis suggest area_s for 
further investigation into the effect of mannitol and other agents on A-
LAK cell uptake into the liver following regional infusion. 
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Chapter 1 Literature Review 
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1.1 Introduction 
LAI< cells, produced by culture of lymphocytes with a high 
concentration of IL-2 have been demonstrated to have broad cytotoxic 
activity against a wide variety of tumour cells (Lotze et al 1981; Grimm 
et al 1982; Rosenstein et al 1984; Lafreniere et al 1985; Mule et al 1985; 
Shu et al 1985; Papa et al 1986; Itoh et al 1986; Salup et al 1986; 
Vujanovic et al 1988b). LAI< cells lyse tumour cells m vivo after 
gaining access to the target cells by extravasation through the 
microcirculation (Harcel et al 1991; Basse et al 1991a). Clinical studies 
using LAI< cells with IL-2 have shown therapeutic value in cancer 
treatment (Rosenberg et al 1986a; 1986b; Benyunes et al 1993; Schoof et 
al 1993). However, systemic LAK/IL-2 therapy is associated with 
significant toxicity which is associated with the very large number of 
cells and high doses of rIL-2 infused (Rosenberg et al 1987; Kuebler et al 
1993; Villani et al 1993). One solution to this problem may be the 
regional administration of LAK cells, possibly together with factors 
which enhance the distribution of LAI< cells to the target organ. 
Studies have shown that regional infusion of LAI< cells could result in 
more effector cells accumulating at the target sites, thus decreasing the 
dosage of LAK cells and IL-2 required and minimising some side 
effects. Regional IL-2/LAK cell infusion has also been shown to be 
associated with anti-tumour effectiveness and lower toxicity 
(Lafreniere et al 1985b; Ettinghausen et al 1985; Basse et al 1991b; 
Kuppen et al 1992; Keilholz et al 1992; Scudeletti et al 1993; Yamamoto 
et al 1993). Local injection of LAK cells shows accumulation of injected 
cells at the tumour sites and tumour regression (Yoshida et al 1988; 
Basse et al 1992b; Hayakawa et-' al 1992; Belli et al 1992; Ibayashi et al 
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1993) s~ggesting that the accumulation of effector cells in the tumour is 
an important factor. 
LAI< cells have a limited pattern of migration after systemic 
administration with 47% accumulation in lungs 2h after infusion and 
then redistribution into liver 24h after infusion (Maghazachi et al 
1988c, 1988b; Felgar et al 1990; Takai et al 1988). The limited distribution 
of LAI< cells inhibits their optimal tumouricidal effect in viva. This 
pattern may be the result of decreased extravasation of LAK cells 
because of their large size and high rigidity (Sasaki et al 1989). Mannitol 
has been shown to open the Blood-Brain Barrier by a mechanism 
involving increase of intercellular spaces between capillary endothelial 
cells (Franceschini et al 1988). In this study we investigated the effect of 
intraportal mannitol on the distribution of LAI< cells infused into the 
portal vein. 
During the course of these experiments there were not many reports 
concerning infusion of LAI< cells regionally and no report of using 
reagents to increase cell distribution. Recently adoptive 
immunotherapy has been delivered by local infusion. In the near 
future the utilization of LAK/IL-2 may be combined with factors which 
could improve their distribution, and with some reagents which could 
enhance LAK cell effectiveness. 
The results of this study may lead to improvement in the effectiveness 
of adoptive immunotherapy, by determining an effective way of 
delivering effector cells into the tumour-bearing host. The generation 
of adequate numbers of highly cytotoxic cells, and the efficient delivery 
. . 
of these cells in viva, are key factors that require improvement in 
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adoptive immunotherapy. This study was aimed at investigating a 
possible method of increasing LAI< cell distribution into particular 
organs and therefore to tumour sites in order to improve the 
tumouricidal activity of LAK cells in vivo. 
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1.2 Development of Adoptive lmmunotherapy for Cancer 
Using LAK Cells and IL-2 
Adoptive immunotherapy for cancer is a therapy aimed at destroying 
cancer cells by transfer of activated antitumour lymphocytes into the 
tumour-bearing host. As early as the 1960's there were some studies 
which found that the intravenous delivery of lymphocytes from 
tumour cell-immunised mice into syngeneic tumour-bearing mice 
could mediate the regression of tumours. For example the treatment of 
fibrosarcoma in the rat with immune T-lymphocytes (Delorme et al 
1964). These animal studies suggested that similar therapy could be 
used in human malignancy, however alternative methods for 
obtaining tumour-sensitised lymphocytes had to be developed. In 
1970's, anti-tumour cytotoxic cells were obtained by sensitising the 
lymphocytes in in vitro culture with tumour cells, MLTC (Treves et al 
1975; Berenson et al 1975; Gillis et al 1977; Ruscetti et al 1977; Zarling et 
al 1979; reviewed in Wilkinson 1993). In addition, the isolation of the 
lymphokine that was originally called T Cell Growth Factor (TCGF), 
now named interleukin-2 (IL-2), revealed that TCGF in the absence of 
tumour cells could stimulate lymphocytes to become cytotoxic against 
tumour cells (Aarden et al 1979). TCGF made it possible to maintain 
cytotoxic lymphocytes in long-term culture (Morgan et al 1976; Gillis et 
al 197.8; Watson et al 1979). 
In the early 1980's, purified IL-2 was found as a glycoprotein of MW 
16,000 (Taniguch et al 1983; Louis et al 1983), and the IL-2 receptor was 
isolated (Uchiyama et al 1981; Leonard et al 1982). IL-2 is synthesised 
and secreted by mitogen- or antigen- activated Th lymphocytes (Smith 
- . 
et al 1980). The availability of large quantities of highly purified IL-2 (r-
s 
IL-2) was made possible by recombinant-DNA technology. IL-2 was 
found to promote the proliferation and activatio~ of antigen-
stimulated T cells (Yron et al 1980; Cheever et al 1981) and to stimulate 
the proliferation of lymphocytes from non-immunised donors, and to 
provide them with the capacity to recognise and lyse a variety of 
tumour cells (Lotze et al 1980,1981; Rosenstein et al 1984). The activated 
cells which were raised from non-antigen-stimulated lymphocytes 
were described as Lymphokine-activated Killer (LAK) cells (Grimm et 
al 1982). The possibility now arose of utilizing LAK cells in adoptive 
immunotherapy. LAK cells could be continuously stimulated in vivo 
by infusion of IL-2 systemically (Ettinghausen et al 1985a, 1985b) and 
could be produced by co-cultivation of peripheral blood lymphocytes 
with IL-2 in vitro. The generation of LAK cells both in vitro and in 
vivo has the advantage that it is unnecessary to pre-sensitise the 
effector cells with tumour cells. LAK cells kill tumour cells in a non-
MHC-restricted manner (Hersey et al 1987). 
In 1984, Rosenberg et al at the National Cancer Institute transferred 
LAK cells into murine tumour models and reported the first 
demonstration that lymphokine-activated killer cells, activated in 
vitro by IL-2, can inhibit the growth of established melanoma 
pulmonary metastases (Mazumder et al 1984). Systemic administration 
of xenogeneic IL-2 together with in vitro-sensitised and IL-2-expanded 
lymphocytes in animals resulted in regression of metastases (Donohue 
et al 1984). Both LAK cells and sensitised IL-2-activated lymphocytes 
have tumouricidal activity in vivo. LAK cells and IL-2 infusion has 
also been used (Mule et al 1985). 
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Administration of high dose IL-2 alone resulted in significant toxicity. 
In humans, initial systemic administration of recombina~t IL-2 at high 
doses over short periods of time showed the rapid half-life of IL-2 and 
it's toxicity in vivo. There was no detectible LAK cell activity in 
peripheral blood after short term administration -of IL-2. However 
there was an increase in the number of lymphocytes and their in vitro 
responsiveness to IL-2 (Lotze et al 1985; Atkins et al 1986). The 
requirement of high dose of IL-2 (over 500U/ml in vitro) to produce 
LAK cells made it impossible to generate them in vivo because of the 
toxicity. Many efforts have been made to modify the t!eatment protocol 
of IL-2 administration to optimise immune effects and decrease 
toxicity. In murine models it was demonstrated that prolonged 
administration of IL-2 at tolerable doses could activate sufficient in 
vivo NK/LAK activity compared with a few days administration of 
very high dose IL-2 (Ettinghausen et al 1986; Nishimura et al 1987; 
Talmadge et al 1987). It was also shown in humans that prolonged 
administration of low doses of rIL-2 resulted in selective expansion of 
NK cells in vivo with minimal toxicity (Caligiuri et al 1991). However 
large numbers of LAK cells could be generated in vitro. Provision of 
IL-2 together with administration of large quantities of LAK cells 
grown in vitro was more effective and less toxic (Mule et al 1984, 1985, 
1986b). The antitumour effect of IL-2 appears to result from the action 
of LAK cells in vivo (Rosenberg et al 1985a; Ettinghausen et al 1985a, 
1985b; Mule et al 1985; Hank et al 1988; Da Pozzo et al 1992). 
It was demonstrated in preclinical studies that combined treatment 
using LAK cells and IL-2 is effective for tumours of distinct histological 
types such as sarcoma, adenocarcinoma and melanoma, and for both 
immunogenic and nonimmunogenic tumours (Papa et- al 1986; 
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Lafreniere et al 1985b; Shu et al 1985). Evidence of efficacy of this 
treatment was also obtained in established metastatic tu~ors in liver, 
lung, kidney and brain (Lafreniere et al 1985a; Papa et al 1986; Salup et 
al 1986; Takai et al 1988). A direct relationship existed between the 
number of LAI< cells transferred, the amount of IL-2 given, and the 
therapeutic effect achieved in murine models (Mule et al 1985). 
Based on the knowlege from animal experiments, immunotherapy 
using LAK cells in conjunction with IL-2 was administered for the 
treatment of selected patients with advanced metastatic tumour. 
Rosenberg reported the result of their initial clinical trial which 
resulted in some responses in patients with colorectal cancer, 
malignant melanoma, renal cell cancer, and lung adenocarcinoma 
(Rosenberg et al 1985a, 1986a, 1986b). In 1987, Rosenberg et al reported 
their progress in treatment of patients with advanced cancer. In many 
patients the administration of these cells and IL-2 was limited by the 
toxicity of IL-2. This side effect resulted in a generalised capillary 
permeability leak syndrome. Further efforts were made to decrease the 
toxicity and complexity of this therapy. 
The role of adoptive immunotherapy in order to achieve significant 
tumour responses with acceptably low toxicity depends on a successful 
refinement of methodology and protocols. Such refinement may 
include more efficient delivery of LAI< cells to the target organ. It has 
been shown that low dose IL-2 plus _LAK cells in immunotherapy has 
greater efficacy (Schoof et al 1988). Thompson et al 1992 found that a -
longer maintenance phase of IL-2 at a lower dose is associated with 
significantly less toxicity without a loss of therapeutic efficacy. It has 
also been shown that purified -populations of A-LAI< cells are more 
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effective in reducing established lung or liver metastases in rat models 
(Schwarz et al 1989). Rosenberg et al 1986c showed that LAK cells 
derived from lymphocytes exposed to tumour cells (such as tumour 
infiltrating lymphocytes) had greater tumoricidal effect than peripheral 
blood lymphocyte-derived LAK cells. Local adoptive immunotherapy 
by direct injection of LAK cells and IL-2 into brain tumours was found 
effective and had low toxicity (Yoshida et al 1988; Ibayashi et al 1993). In 
humans the effect of systemically infused LAK cells is far less in brain 
tumours (Monod et al 1992). In a later murine model with 
intracerebral metastases it was shown that there was no response to 
systemic infusion of LAK cells and IL-2 (McCutcheon et al 1990). The 
fact that histological examination of brain tissue did not reveal 
lymphocyte infiltration indicated that the effector cells were not 
delivered into tumour sites in brain by systemic infusion. The fact that 
there was no discernible correlation between in vitro target cell lysis by 
LAK cells and theraputic efficacy in viva (Papa et al 1986; Nakano et al 
1991) suggests that the effector cells may not reach the target organ in 
sufficient number in viva. Lack of response is not the result of loss of 
effectiveness in viva because it has been shown that there was 
corresponding in viva and in vitro susceptibility of murine tumours 
to lysis by LAK cells (Papa et al 1986). The tumour cells which appeared 
to be sensitive to LAK cells in vitro do not appear to be resistant to 
LAK cells in viva (Mule et al 1986). It is most likely the result of 
insufficient LAK cell infiltration into tumour sites. The extravasation 
of LAK cells into the tumour may be one of the important steps for 
achieving tumour damage. 
The studies of adoptive immunotherapy in humans using LAK cells 
and IL-2 are continuing. It has been shown that this immunotherapy 
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results in partial or complete regression (PR and CR) of several types of 
tumours: prostatic carcinoma and associated pulmonary metastases 
(Tjota et al 1991); advanced renal cell carcinoma (Weiss et al 1992; 
Engelstein et al 1992); primary or metastatic liver carcinoma (Miya et al 
1992; Foon et al 1992); non-Hodgkin's lymphoma (Weber et al 1992). 
Local and regional infusion of LAK cells and IL-2 appears to result in 
more responses because local infusion may be associated with greater 
accumulation of effector cells at the tumour site. Intrahepatic LAK 
cells inhibited the growth of metastatic tumours in the liver in some 
patients with cancers of the gastrointestinal tract (Tsugita et al 1990), 
and resulted in CR and PR in advanced liver metastatic or primary 
cancer (Han et al 1991; Keilholz et al 1992; Yamamoto et al 1993). 
Regional arterial administration of LAK cells also resulted in 
metastatic regression (Hayakawa et al 1991, 1992). Local adoptive 
immunotherapy using A-LAK cells and IL-2 in a nude mouse model of 
human squamous carcinoma of the head and neck resulted in 
complete tumour growth inhibition (Sacchi et al 1991). In a report on 
human malignant pleural mesothelioma treated with the local A-LAK 
immunotherapy, there was a reduction of the malignant pleural 
effusion (Yanagawa et al 1991). 
The additional use of different lymphokines or cytokines may result in 
augmentation of effectiveness of LAK cells and IL-2. The combination 
with interferon-alpha (IFN-alpha) but not tumour necrosis factor-
alpha (TNF-alpha) showed augmentation of the effect of LAK cells in 
vitro (Wanebo et al 1991) and in vivo (Puri et al 1991). Kato et al 1991 
reported that appropriately timed pretreatment of tumour-bearing 
mice with TNF-alpha augmented the anti-tumor efficacy of LAK cells. 
In vitro the combined application of IL-2 and IFN-alpha, IFN-gamma 
or TNF-alpha significantly improved the cytotoxicity of A-LAK cells to 
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human leukemia cells (Teichmann et al 1992). IL-1 and IL-3 may also 
increase the effect of IL-2 (Marumo et al 1992; Okuno e~ al 1992);. IL-7 
was found to be able to induce significant LAK activity after bone 
marrow transplantation (Pavletic et al 1993). 
The combination of chemotherapy with LAK cells and IL-2 adoptive 
immunotherapy may also result in additive effects (Yamaue et al 1991; 
Wakizaka et al 1992; Gazit et al 1992). Splenic or hepatic arterial 
injection of IL-2 with chemotherapeutic agents such as 
cyclophosphamide (CY), 5 fluorouracil (SFU) and mitomycin C (MMC) 
resulted in more LAK/NK activity in PBL in comparison to injection 
of IL-2 alone (Okuno et al 1991). Low-dosage CY seems increasing the 
LAK activity with IL-2 in patients with advanced malignancies of 
varying types (Abrams et al 1993). Lithium can be used as a new 
immunomodulator for cancer immunotherapy (Wu et al 1992). By 
conjugation of LAK cells with anti-tumour monoclonal antibody, LAK 
cell killing activity against tumour was specifically enhanced (Shiraiwa 
et al 1991; Takahashi et al 1993; Weiner et al 1993; Watanabe et al 1993). 
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1.3 In Vitro Production and Characterisation of LAK Cells 
1.3.1 Introduction 
LAI< cells are generated by culturing lymphocytes with IL-2 for several 
days. Since the description of the LAI< cell phenomenon there has been 
extensive investigation of LAI< cells including their characterisation 
and functions. This section summarises work on the morphology, the 
cell surface characteristics and the tumouricidal activity of LAI< cells 
and LAI< cell precursors. 
1.3.2 Morphology and cell surface characteristics of LAK cells 
and LAK precursors 
1.3.2a LAK cell morphology 
It is generally accepted that among whole lymphocyte populations, 
LGL/NK cells are the main precursors of LAI< cells. NK cells have the 
same morphology as LGL in the human and rat (Reynolds et al 1981a; 
Timonen et al 1981). LGL/NK cells (diameter 10-lSµm) are slightly 
larger than small and medium-sized lymphocytes and they have a 
relatively high cytoplasmic to nuclear ratio, an eccentric reniform 
nucleus and weakly basophilic cytoplasm with several azurophilic 
granules. Human LGL have a very typical lymphocyte staining pattern 
for tartrate-inhibitable acid phosphatase (Timonen et al 1981). 
Macrophages can be distinguished from LGL on the basis of their large 
size (15-20µm), a more indented nucleus, and vacuolar cytoplasm. NK 
cells differ from small lymphocytes in expressing prominent 
azurophilic granules and their low density (Shau et al 1985). 
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In response to culture in high concentrations of rlL-2 (500-lOOOU /ml), 
LGL/NK cells differentiate into highly active cytotoxic c~lls which·have 
been termed LAK cells. The LAK cells have similar morphology to 
LGL/NK. Morphological analysis of human A-LAI< cells indicate that 
these cells have the morphology of LGL with abundant cytoplasm and 
prominent cytoplasmic granules (Melder et al 1988), vacuolate 
cytoplasm and an undulating surface (Vujanovic et al 1988c). Sasaki et 
al 1989 have demonstrated that LAK cells have a greater mean 
diameter than nonactivated LGLs 
1.3.2b Cell surface markers 
Extensive studies analysing the surface phenotype of LAK progenitors 
and effector cells have been obtained in three species: human, rat and 
mouse. 
In humans, most of the LAK cell progenitors from peripheral blood 
lymphocytes have the same characteristics as LGL/NK cells, and the 
human effector LAK cells also express the same phenotype as activated 
NK cells. Phillips et al 1986 and Ortaldo et al 1986 indicated that LAK 
progenitors in human peripheral blood are LGL/NK cells expressing 
the surface markers NKH1/Leul9 and CD16. CD16 antigen (Leull) has 
been found on almost all activated NK cells (Lanier et al 1983). NKHl 
antigen (Leu19) has been detected on virtually all NK cells and also on 
a small subpopulation of CD3+ T cells (Hercend et al 1985; Schmidt et al 
1986). Itoh et al 1985a showed that LAK precursor cells are Leu-
1.1 +(CD16) lymphocytes with NK activity. The progenitors did not 
express the pan-T-cell markers CD3 or CDs. The activity of LAK cells 
developed from cell populations without pan-T marker positive cells 
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(OKT3 or Leul) was found to be greatly augmented (Grimm et al 
1983a). Killer cell precursors were also found in Leulla+ (CD16) and 
Leu7+ NK subsets, but not in Leu4+(CD3) or Leu3a+(CD4) T 
lymphocytes (Itoh et al 1986). The majority of LAI< activity is mediated 
by NK cells that express the NKH1/Leul9, but not by T cells that 
express CD3. Talmadge et al 1986 found that the subpopulation of 
lymphocytes most responsive to high doses of rIL-2 (> lOOU I ml) 
comprised LGLs, the morphologic homologue of natural killer cells. 
Lotzova et al 1987 further confirmed that human IL-2-stimulated 
active NK cells displayed LGL morphology and had CD16 and 
NKH1/Leu19 (CD56) cell surface phenotype. For human A-LAI< cells, 
phenotypic analysis indicates that a majority of these cells express the 
CD3-Leul9+ phenotype and a substantial proportion of Leul9+ cells 
expressed CD16 antigen (Melder et al 1988). Thus the progenitors of 
LAK activity in human peripheral blood are mainly LGL/NK with 
CD3-, CD16+, NKHl+ (CD56) phenotype. 
Grimm et al 1983a found that human LAI< progenitor cells were 
present in lymphoid organs containing few active NK cells. They were 
null cells, distinct from NK cells or classical thymus-derived T-cells. 
Thymus derived LAI< cells are low to medium density lymphocytes, 
CD3 negative, and they possess the NK-associated marker NKH1/Leul9 
(CD56), however they lack most NK-associated markers CD16 
(HNKl/Leull and B73.l) (Ramsdell et al 1987). 
In rats, Vujanovic et al 1988a showed that the major cell population 
activated by rIL-2 is the LGL/NK cell. These cells appeared to represent 
the major population of cells in blood or spleen which generated broad 
antitumour (LAK) cytotoxicity. Highly purified populations of 
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peripheral blood LGL express surface markers of rat NK cells such as 
OXs+, Laminin+, asialo-GMl +,but are OX19-, Rl-3B3-, W3/2S-, la-, Sig-. 
They are fully capable of generating high levels of LAI< activity by 3 to 5 
days in culture with rIL-2. Analysis of the LAI< effector phenotype by 
cell sorting demonstrates that the majority of cells with LAI< activity 
are OXs+, Laminin+, asialo-GMl+, OX6+ but not those of mature Tor 
B cells (i.e., OX19, Rl-3B3, W3/25, la, Slg.). LGLs have been shown to be 
highly associated with NK activity (Reynolds et al 1981a). LGLs express 
OXs, asialoGMl, L-C, and W3/13 antigens. Very few LGL express the 
W3/25, Thyl.l, la, or Slg antigens (Reynolds et al 1981b). Cantrell et al 
1982 found that LGLs were OXs+ and W3/13+, but W3/2S-. Rat LGL are 
not typical T cells, B cells, monocytes, or PMN. They share some cell 
surface markers (eg OX1s) with T cells (Reynolds et al 1981b). Rat 
cytotoxic T lymphocytes were OXs+, W3/2S-, la-, Thyl- (Gilman et al 
1982). Woda et al 1984 demonstrated that rat NK cells do not express 
the T cell-specific membrane protein OX19. The functional NK 
population was OX19- OXs+. 
Vujanovic et al 1988 described a new method for the purification and 
rapid expansion of LGL by isolating the plastic adherent IL-2 stimulated 
LGL and then continuing culture of these cells for several days. These 
LAI< cells are called adherent LAK (A-LAK) cells which are found to 
have exceedingly high levels of broad antitumour cytotoxicity. They 
express surface markers of rat NK cells such as OXs(CDs)+, asialoGMl +, 
laminin+, but are OX19(CDs)-, Rl-3B3 (CDst, W3/25(CD3t, OX39(CD25t 
, la-, and Ig- (Vujanovic et al 1988c). Further investigation of the A-
LAK phenotype has also shown that 90-100% of purified A-LAK cells 
express OXs, asialo-GMl, laminin, and the structure identified by 
monoclonal antibody 3.2.3, surface markers which are all common to 
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rat LGL/NK cells. In contrast, neither OX19(CDs), W3/25(CD4), OX41 
(macrophage specific), nor lg was expressed on these cells. All A-LAK 
cells were LGL's (Schwarz et al 1989; Chambers et al 1989). It seems that 
OXs and 3.2.3 are the most specific for rat LAK cells (for CDs and CD16) 
at the present time. 
In the mouse, evidence suggests that NK cells are the progenitors of 
cells with LAK activity. The progenitor cells were asialo-GMl +, Lyt2-, 
L3T4-, Ja-, lg-, and Thy-1-, a phenotypic pattern characteristic of mouse 
NK cells, but not Tor B cells (Yang et al 1986; Salup et al 1987). Hackett 
et al 1986 found in normal adult mice that splenic NK activity was 
found in the NK-1.1 + fraction and also in asialo GMl + cells. Purified 
NK-1.1 + cells showed a homogeneous population, each cell containing 
one to four cytoplasmic granules. Data on the effector phenotype of 
mouse LAK cells also indicate that they express surface markers similar 
to those of activated NK cells (asialo-GMl+, Thy-1+, 1a-, FcR+) (Yang et 
al 1986). Precursors of LAK cells are Thyl + (Rosenstein et al 1984). 
Both Thyl- and Thyl + murine LAK precursors can give rise to LAK 
cells which are cytotoxic to tumour cells (Ballas et al 1987). Rosenstein 
et al 1984 showed that LAK lytic ~ctivity was due to Thyl +, Lyn-2+ 
cells. Ballas et al 1987 and Ting et al 1986 delineate at least two different 
LAK precursors, one Thyl-, Lyt2-, aGMl + (NK like), and another 
Thyl +, Lyt2+, aGMl + (T cell like). However these divergent results 
probably resulted from the different culture , methods for generating 
LAK cells. Other studies in mice have suggested a distinction between 
NK cells, cytotoxic T-lymphocytes and cells with LAK activity 
(Merluzzi et al 1985; Andriole et al 1985; Ballass et al 1986; Merluzzi et 
al 1986). 
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In humans and in rats, several investigators have suggested that 
LGL/NK cells are derived from noncytotoxic agranular precursor cells 
which are called large agranular lymphocytes (LAL). Human thoracic-
duct lymphocytes are devoid of NK activity, but when incubated with 
IL-2, develop into LAK cells (Andriole et al 1985). Lotzova et al 1987 
found that impairment of NK cells tumour-binding and lytic activity 
in leukemia patients could be corrected by culture of peripheral blood 
effector cells with IL-2. Thus non-cytotoxic pre-LAK cells exist. That NK 
activity could be generated from nongranular precursors was first 
demonstrated by Shau et al in 1985. These workers found that after 
selectively depleting LGL from human PBL with a lysosomotropic 
amine (LME) and subsequently culturing the LME-resistant cells with 
IL-2, LAK cells were obtained from the culture. The precursors are 
probably LAL because these cells have the same low buoyant density as 
LGL/NK cells, and thus can be selected together with LGLs from Percoll 
density gradient separation columns. However they are resistant to 
LeuOMe or LME which depletes LGL/NK cells. These cells are distinct 
from mature NK cells which express HNKl, OX16 (B73.l, Leu-llb) and 
OKMl markers. Gray et al 1985 also found that depletion of NK activity 
from human PBL does not impair the development of LAK activity. 
That development of LAK activity does not require mature NK cells is 
showii. by the generation of activated LAK cells from fresh thymocytes 
and lymph node cells which lack natural cytotoxic activity. Thymocyte 
LAK precursors are of low to medium density, with their phenotypic 
identification devoid of OX16 and NKHl, T cell surface marker OXl 
negative, and predominantly OX3-negative (Gray et al 1985; Ramsdell 
et al 1987). These phenomena suggest that the precursors are LAL. LAL 
are also found to be the immediate precursor cells for LGL/NK cells in 
rats (Maghazachi et al 1988a). These authors found that LAL, LGL/NK, 
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and LAK cells appear to represent sequential developmental and 
activation stages. In response to rIL-2, enriched populati.ons of splenic 
LAL can first differentiate into LGL with NK activity and then these 
LGL/NK cells can be further differentiated and/ or activated by high 
doses of rIL-2, to become the cells with LAK activity (Maghazachi et al 
1988a). These LAL express asialo-GMl but only some of them express 
OXS (30%) which are expressed on virtually all rat LGL/NK cells 
(Vujanovic et al 1988c; Woda et al 1984; Reynolds et al 1981b; 
Vujanovic et al 1988a) and no surface laminin. They lack the T cell 
surface marker OX19. Kumagai et al 1982 also found LAL were asialo-
GMl + but had no NK activity.. During the transformation of LAL into 
LGL/NK, these cells acquire LGL/NK cell surface markers as well as 
NK activity. Andriole et al in 1985 also found that there was no 
correlation between the presence of NK cells and the capacity to 
generate LAK cells after in vitro incubation of splenocytes with IL-2 in 
some immunodeficient mouse strains. It has also been shown that 
active NK cells can be induced from precursors from bone marrow 
(BM). BM is devoid of, or has a low frequency of cytotoxic NK cells 
(Hackett et al 1985, 1986). Thymocytes and bone marrow cells need a 
longer time to generate LAK activity in culture with IL-2 (Vujanovic et 
al 1988b). LAL may comprise a major source of LAK progenitors in 
lymphoid populations having few LGL or mature active NK cells. 
1.3.3 Production of LAK cells in vitro 
1.3.3a Isolation of LAK precursors from whole lymphocyte populations 
LAK cells have been generated from a variety of organs and tissue 
sources in different specfes. In l:mman LAK activity against tumour has 
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been generated from lymph node, thymus, thoracic duct cells, bone 
marrow, spleen and PBL (Grimm et al 1983b). Since .the LAL and 
LGL/NK cells are the major precursors of LAK cells, information about 
their presence in different organs provides a guide for the selection of 
tissue for LAK cell generation in vitro. In rat the LGL precursor 
frequency in different organs has been shown to be in the order of 
peripheral blood> spleen> peritoneal exudate> lymph node> thymus 
or bone marrow (Reynolds et al 1981a). The frequency of LGL and NK 
activity in different strains appears different. The low NK activity in 
older animals or in strains with low NK cells is not always associated 
with low number of LGL (Grimm et al 1983). Grimm et al 1983 found 
in the W /Fu rat that the frequency of LGL among the spleen cells is 2-
6%, and among PBL is 4-14%. Timonen et al 1981 also reported the 
frequency of LGL among human blood leukocytes varied from 2% to 
6%. 
There are several different techniques available to isolate LGL from 
mixed leukocyte populations. Nylon wool (NW) was described as a 
material which could induce B cells and macrophages to adhere to it. 
LGL/NK cells are of low density because of their relatively high 
cytoplasmic: nuclear ratio, and can ~e separated from higher density 
lymphocytes on Percoll discontinuous density gradients. Different 
types of gradients have been used. In a 7-step gradient, the highest 
frequency of LGL (82%) with enriched NK activity was found in 
fraction 2. In a 4-step gradient, the fraction 2/3 contained 73% LGL 
(Reynolds et al 198la}. Human LGL could be enriched to a purity of 
>90% by depleting high affinity rosette-forming cells from the cells 
collected from low density Percoll fractions (Timonen et al 1981). 
Timonen et al 1982 found that rat LGL could be further enriched by 
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depleting high affinity sheep erythrocyte rosette-forming cells from the 
LGL-enriched Percoll fractions, resulting in >90% purity. Other 
techniques are available to obtain the LAK precursors. One technique is 
to deplete the T cells from NWP lymphocytes with monoclonal 
antibody (Mab). The Mab Rl-3B3 can react with T cell membrane 
antigens but not with that of LGL. Use of this Mab with complement 
can remove pan T cells. Another technique makes use of LGL-selective 
antibodies and cell sorting (Ortaldo et al 1981). The disadvantages of 
this technique are the small recovery of LGL and the risk of changing 
cell membrane structure and function. 
In 1988 Vujanovic et al first described a new procedure for the 
purification and rapid expansion of LGL. The antitumour effector cells 
were generated by isolating IL-2 stimulated plastic adherent LGL then 
continuously culturing these for several days. They found that one of 
the first responses of a small subpopulation of cells (LGL) to IL-2 is 
their adherence to the plastic surfaces of a culture flask. After 24-48h, 
about 4.5% of input cells could adhere to the plastic surface and 97% of 
these adherent cells are LGLs. Forty eight hours culture seems to be the 
optimal time for selecting the adherent cells for expansion. These LGLs 
express surface markers of rat NK cells. When plastic-adherent 
LGL/NK cells were cultured over 3-4 days in IL-2 in conditioned 
medium, these cells expanded 30-100 fold and they comprised highly 
purified LAK cells with a very high level of broad antitumour 
cytotoxicity. Schwarz et al 1989 showed that purified populations of A-
LAK cells have superior effect to LAK cells in reducing established 
metastases in rat models. It was demonstrated that by culturing hum an 
MNC from healthy individuals and cancer patients, A-LAK cells that 
have more potent antitumour cytotoxic function in vitro (compared to 
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LAI< cells prepared in a conventional manner) are obtained. This 
relatively new technique has been utilised in human A-LAI< cell 
production (Melder et al 1988). 
1.3.3b Factors influencing LAK cell proliferation 
It has been described that LAK cells could be generated by coculture of 
LAI< precursors with IL-2 in vitro, and that IL-2 alone directly 
stimulates LAK precursors to become cytolytic effector cells (Grimm et 
al 1983b). Recombinant human interleukin-2 in the presence or 
absence of additional stimuli was found to be able to induce and 
maintain the proliferation of human PBL. However when low 
concentrations (<lOU/ml) of interleukin-2 was used, proliferation was 
observed only when additional signals (antigen, mitogen) were 
provided (Talmadge et al 1986). Higher concentration (>lOOU/ml) of IL-
2 stimulated the proliferation of LAK cells in the absence of exogenous 
lectin, antigen or allogeneic serum. Rosenstein et al 1984 also reported 
that IL-2 is the key stimulus for the generation of LAI< cells. The lytic 
capacity of LAK cells is due only to IL-2 and not Con A, fetal calf serum 
or other lymphokines. However Vujanovic et al 1988c suggested that 
factors in addition to IL-2 present in conditioned medium may be 
required for optimal expansion of A-LAK cells. LGL synthesise DNA 
and proliferate very rapidly in response to rIL-2 in culture (Talmadge et 
al 1986). Up to 85% of adherent LGL were synthesising DNA in the 
culture (Vujanovic et al 1988c). The reaction of LGL to IL-2 seems 
dependent on the expression of the TAC receptor on the cell 
membrane (Talmadge et al 1986). The cells from discontinuous Percoll 
gradient fraction-2 (>90% LGL) showed expression of the TAC receptor. 
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There is evidence that the presence of some other cell populations in 
vitro may influence the LGL proliferation. Macrophages have been 
shown to have suppressive effects on NK activity in vitro. Vujanovic 
et al 1988c found that both suppressor T cells and monocytes in bulk 
culture inhibit LAI< cell generation. Triozzi et al 1991 found that 
human monocytes markedly inhibit LAI< cell expansion in PBL 
culture with IL-2. The addition of monocytes to IL-2 stimulated 
lymphocytes decreased LAK cell activity. This inhibition was enhanced 
in the presence of rIFN gamma (Weng et al 1991). 
1.3.4 Tumouricidal activity of LAK cells in vitro and in vivo 
Lymphokine-activated Killer (LAK) cells are immune effector cells 
which can non-specifically lyse neoplastic cells including NK-resistant 
tumour cells. In vitro, LAK cells have been shown to have broad 
cytotoxic activity against a wide variety of tumour cells. Rosenstein et 
al 1984 found that murine LAK cells produced by culture of 
lymphocytes with IL-2 manifested significant lysis of several fresh NK-
resistant syngenic cell lines (MCA-102, MCA-106, EL-4 lymphoma) and 
the NK-sensitive YAC target. Lafreniere et al 1985 and Papa et al 1986 
demonstrated that LAK cells can mediate anti-tumour effectiveness 
despite the lack of specific antigen recognition by the immune system 
to the MCA-102 sarcoma which is a non-immunogenic tumour. LAK 
cells can effectively lyse autologous fresh tumour cells in addition to 
allogeneic fresh tumours and all cultured tumours tested, including 
those NK-resistant targets, in a 4h chromium-release assay (Grimm et 
al 1982; Lotze et al 1981). Vujanovic et al 1988b found that rat LAI< cells 
had very high levels of cytolytic activity to a variety of tumour cells 
including in vitro tumour lines raised from various tissue origins 
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from rat, mice or human. LAK cells could easily lyse fresh syngenic 
ascitic or solid tumour cells. LAK cells were unable to lyse fresh 
normal targets. LAI< cells had antitumour activity in standard adoptive 
transfer (Winn-type) assays to an NK-resistant syngenic 
adenocarcinoma-MADB106 (Vujanovic et al 1988b). Human MNC 
incubated in the presence of high concentrations of rIL2 develop broad 
cytotoxic reactivity against autologous and allogeneic fresh tumour cell 
targets and tumour cell lines (Grimm et al 1982; Itoh et al 1986). The 
broad spectrum of tumour lysis distinguishes LAK cells from that of 
conventional CTL (cytotoxic T lymphocytes) which require the 
recognition of specific antigens and MHC molecules on tumour cells. 
Cytotoxicity of LAK cells has been demonstrated in vivo. LAK cells and 
IL-2 are effective for a variety of histological tumour types (sarcoma, 
adenocarcinoma, and melanoma) and for both immunogenic and 
nonimmunogenic tumours (Papa et al 1986; Lafreniere et al 1985a, 
1985b; Shu et al 1985). Evidence of tumouricidal activity has also been 
obtained in different sites aganst established metastatic tumours such 
as the hepatic metastases (Lafreniere et al 1985), pulmonary metastases 
(Papa et al 1986), renal (Salup et al 1986), and brain metastases (Takai et 
al 1988). A direct relationship has been shown between the number of 
LAK cells transferred, the amount of IL-2 given and the therapeutic 
effect achieved in murine models (Mule et al 1985). 
The mechanisms responsible for the tumouricidal effect of LAK and A-
LAK cells remains obscure, but clearly require cell : cell contact and this 
is dependent on gaining access to the target cells. In vivo this includes 
the process of LAI< cells extravasation through the microcirculation. 
Basse et al 1991b have demonstrated that adoptively transferred A-LAK 
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cells were able to migrate out of tumour vessels and establish direct 
contact with tumour cells within 16h of injection. These authors· also 
obtained direct evidence that A-LAK cells migrated to and heavily 
infiltrated metastases of murine tumours in different organs. 
Ultrastructural study of LAK cell lysis has shown that LAK cells make 
close contact with the target cell followed by the delivery of as yet 
unknown products into the tumour cells (Chen et al 1991). Harcel et al 
1991 found that the frequency of LAK cells in the developing liver 
metastases was 3-6 times higher than that in the surrounding normal 
liver tissue, which indicated that LAK cells lyse tumour cells by direct 
attack. In liver metastasis-bearing animals, very few A-LAK cells were 
seen in normal and metastatic tissue following systemic injection. 
Lotzova et al 1987 found that following systemic injection, very few 
LAK cells arrive at the sites of tumour and relatively small fraction of 
total injected cells localised in tumour. Basse et al 1991b indicated that 
the effectiveness of LAK cells in viva depands on the route of 
administration. Substantial infiltration of lung metastases was seen 
after systemic intravenous injection, whilst significant infiltration of 
liver metastases was seen only after intraportal injection of the A-LAK 
cells, indicating impaired trafficking of systemically injected A-LAK 
cells through the lung capillaries. Sasaki et al 1989 indicated that 
increased rigidity of LAK cells coupled with their large cell size may 
explain the poor localisation of LAK cells into tumour targets in viva, 
because of trapping of the cells in the lungs. Felgar et al 1990 pointed 
out that A-LAK cells do not actively migrate towards tumour sites. A-
LAK cells appeared to enhance suboptimal but ongoing host 
antitumour effector mechanisms by release of cytokines, functioning 
as a form of "helper cell". Sasaki et al 1991 suggested that A-LAK cells 
might induce tumour necrosis by impairment of tumour vascular 
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supply. Jain et al 1989 indicated that cytokines produced by A-LAK cells, 
such as interferon, tumour necrosis factor-alpha (Futami. et al 1991), IL-
2 and granulocyte macrophage colony-stimulating factor, may diffuse 
into the tumour and produce a toxic effect in tumour cells either 
directly or by recruitment of other cytotoxic cells to the area of the 
tumour. 
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1.4 In Vivo Distribution of IAK Cells Infused Systemically or 
Regionally 
Only a few studies of LAK cell distribution following systemic or 
regional infusion have been reported. Studies of cell distribution in the 
rat have shown that purified LAK cells are primarily trapped in the 
lungs 2h after systemic infusion. By 24h, the cells had left the lungs and 
were largely located in the liver and spleen. Forty seven per cent of 
51Cr-labelled purified A-LAK cells injected systemically into syngeneic 
F344 rats accumulated in the lungs 2h after injection, then 
redistributed to the liver and the spleen by 24h (Maghazachi et al 
1988c). Maghazachi et al 1988b found that 51Cr-labelled LAK cells also 
displayed a restricted pattern of distribution, localising mainly in the 
lungs at 2h after iv. injection but redistributing to the liver and the 
spleen by 24h. Labelled LAK cells were rarely recovered from the 
lymphoid tissues, including the peripheral lymph nodes and the 
mesenteric lymph nodes. Felgar et al 1990 analysed tissue distribution 
patterns of purified A-LAK cells in normal and tumour-bearing rats. 
These authors also found that A-LAK cells first migrated to the lungs 
2h after systemic infusion followed by migration to the liver and 
spleen by 24h, in both normal and tumour-bearing rats. Liver 
metastases did not significantly alter the migration pattern of iv. 
administered A-LAK cells. Maghazachi et al 1989 found that 
preincubation of A-LAK cells with certain carbohydrates resulted in 
redistribution of A-LAK cells from the lungs to the liver. They 
suggested that sequestration of A-LAK cells in the lung capillaries 
might be mediated by cell surface receptors. However there is also 
evidence that the capillaries of the lungs and the intestinal tract restrict 
systemically injected LAK cells because of the large size and rigidity of 
these cells (Sasaki et al 1989). 
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Several investigators have studied the migration pattern and tissue 
distribution of cytotoxic cells using different labelling radioisotopes. 
Reynolds et al 1984 demonstrated that 2h following intravenous 
injection, a high percentage of lllin-oxine radiolabelled LGL were 
found in the liver (25.1 %), spleen (17.7%) and lungs (13.5%), and a 
small proportion remained in blood (9.0%). At 24h following 
intravenous injection, more radioactivity was detected in the liver 
(31.9%) and spleen (20.9%), and less in the lungs (6.5%) and blood 
(4.0%). Very little radioactivity was found in the thymus, CLN, MLN, 
SI, or kidneys. Rolstad et al 1986 showed that 0.5h after iv. injection, 
lllJn-oxine labelled LGL located in liver (31.0%), lung (24.0%), spleen 
(11.0%) and in the blood (12.8%) in athymic nude rats. By 24h these 
cells redistributed into liver (38.0%) and spleen (17.0%) with a 
decreased radioactivity in lung (13.0%) and blood (9.3%). Only a very 
low percentage of radioactivity was recovered in MLN and kidney 
(0.3%). The main sites of localisation of [3H]uridine labeled LGL were 
the alveolar walls of the lungs and the red pulp of spleen. There was 
no radioactivity detectable in the circulatory areas of T lymphocytes 
such as lymph nodes and splenic white pulp (Rolstad et al 1986). Using 
microautoradiography, Takai et al 1988 administered [3H]thymidine-
labelled LAK cells systemically iv. into rats. LAK cells accumulated in 
the lung shortly after administration and then appeared in the liver 
and spleen. By labelling LGL with [3H]uridine, it has been shown that 
2h after systemic iv. injection, trapping of these cells is noted in the 
lungs (26.1 %), liver (22.2%), and spleen (8.5%). By 24h the percentage of 
cells decreased to: lung 10.0%, liver 11.5% and spleen 6.0% (Rolstad et 
al 1986). The decreased radioactivity in these organs correlated with the 
total radioactivity decreasing (from 97.4% in l/2h to 66.4% in 2h 
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followed by 33.9%24h after injection), which suggested a rapid release 
of [3H]uridine from cells (Ettinghausen et al 1985; Rolstad et al 1986). 
Rolstad et al 1986 demonstrated that both 51Cr and lllin-oxine 
radiolabells resulted in a similar distribution pattern for LGL. 
Marincola et al 1988 investigated the distribution of human PBL and 
LAK cell in v iv o in cancer-bearing nude mice by labelling cells with 
lllindium-Oxine. After administration of these cells into human 
pancreatic cancer-bearing nude mice, they found that LAK cells were 
taken up predominantly by liver and spleen, but PBL located mainly to 
lung, kidney, skin and pancreatic tumours. 
Maghazachi et al 1990 investigated the different distribution of LAK 
cells labeled with four radioisotopes: 51Cr; lllin-oxine, 125I-dUrd and 
lllin-Cl. They found that 30min and 2h after systemic iv. injection, 
cells labelled with lllin-oxine had an equivalent distribution into the 
lung and liver, those labelled with 51Cr or 125I-dUrd showed a higher 
accumulation in the lungs, whereas cells labelled with 111In-Cl entered 
into the liver and blood. Twenty four hours after injection, LAK cells 
labelled with 111In-Cl, lllin-oxine or 51Cr redistributed to the liver and 
spleen in variable concentrations. Cells labelled with 125I-dUrd were 
not detected in any organ tested, probably because of the elution of 12sr-
dUrd from the labelled cells after iv. administration. But the regional 
administration of 125I-dUrd labelled cells through portal vein did not 
show the elution of 125I-dUrd from cells (Basse 1992b, 1992a). 
The pattern of in vivo distribution of rat LAK cells is similar to that of 
LGL/NK cells but different from that of activated T cells (Maghazachi 
et al 1988c). Maghazachi et al 1988b indicated that a LAK-like migration 
could be shown by LGL, but both T cells and LAL showed a different 
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pattern of distribution from LGL/LAK cells. Reynolds et al 1984 also 
showed that the distribution of LGL/NK differed markedly from that 
of the other leukocytes. By 2h-4h following transfusion, there were 
significantly more LGL (13.5%) than T cells (6.4%) remaining in the 
lungs and the difference persisted through 48h (5.4% vs 0.8%). Zoller et 
al 1982 suggested that rat LGL have a lower capacity than T or B cells to 
traverse the blood-lymph barrier. The migration pattern of cultured 
pre-immunised CTL is markedly different from immunised cells that 
had not been cultured with IL-2. With an increased CTL frequency after 
culture in MLC with IL-2, the cell migration was progressively 
decreased in spleen, lymph nodes and femurs, while increased levels 
of radioactivity were detected in the lung and liver (Lefevre et al 1987). 
Lotze et al 1980 investigated the migration patterns of human MLC-
generated cells and murine CTL clones cultured with IL-2. The results 
showed that 51Cr labelled murine activated cells were located in the 
lungs 4h after iv injection and redistributed to the liver and spleen 
over the next 24h. When compared with labelled uncultured 
spler:iocytes, the cells cultured with 'IL-2 showed an early increased 
accumulation in the lung. Human activated cells exhibited a similar 
trafficking pattern to cells of the mouse. It was found that only 5-6% of 
infused activated cells could be detected in blood 20min after injection, 
compared to other studies showing 50% of uncultured cells detected in 
the blood shortly after iv infusion. This difference suggests that the 
large IL-2 cultured cells are quickly removed from the circulation. It 
was most likely that activated cells were more easily entrapped by the 
first pass through the capillary bed of the lung. Injection of 51Cr-
labelled cultured CTL resulted in extensive deposition of cells in the 
lungs and had very little associated radioactivity in lymph nodes after 
iv. injection (Lefevre et al 1984). After systemic infusion LAK cells 
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were localised to the lungs but not to the tumour site (Hayakawa 1992). 
These studies generally reveal an accumulation of cells in the lungs 
and a paucity of CTL in lymphoid sites. There are different views as to 
what mechanisms are responsible for the differential entrapment of 
activated cells. Lotze et al 1980 suggested that cell membrane alterations 
may be induced by culturing cells in IL-2 and these changes may 
explain the altered trafficking pattern. The cultured cells are large and 
blastic, and may become trapped in the capillary bed of the lung. 
Comparing the results from studies of in viva LGL or LAK cell 
distribution, after systemic iv. injection, there is a higher 
entrappement of LAK cells in rat lungs (Maghazachi et al 1988c; 
Reynolds et al 1984). Similarly, more activated-T cells are entrapped in 
the lungs than fresh-T cells. LAK cells and activated T cells have a 
relatively large diameter (11.0µm, 9.7µm) compared with LGL (mean 
diameter 7.2µm) and fresh T cells (6.6µm). LAK cells are significantly 
less deformable than other cell types such as nonactivated 
lymphocytes. Cell deformability was independent of cell size. LAK cells 
contain numerous cytoplasmic granules. Both the cell membrane and 
the cytoplasmic factors contribute to the rigidity of LAK cells. Structural 
rigidity is known to influence the behaviour of cells in capillaries, by 
hindering their passage through small capillaries and altering their 
haemodynamic behaviour in postcapillary venules (Sasaki et al 1989; 
Worthen et al 1989). Maghazachi et al 1988b showed that LAK cells may 
have surface carbohydrate-binding protein which allows them to bind 
to endothelial cells lining blood vessels. In summary the reason for the 
early high retention of A-LAK cells in the lung seems to be related to 
the characteristic irregular morphology of A-LAK cells, the high 
rigidity of these cells, and altered cell surface characteristics. 
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The migration of lymphocytes to Peyer's patches and lymph nodes 
appears to be associated with the presence of receptors on lymphocytes 
for high endothelial venules (HEV) (LeFever et al 1984; Lotze et al 1980; 
Zoller et al 1982). The paucity of production of CTL lymph node 
lymphocytes may result from the loss of HEV receptors and other 
differences in cell surface carbohydrate composition (Carroll et al 1983). 
McCoy et al 1990 found that rat LGL/NK cells cultured with IL-2 results 
in altered expression of specific cell-surface carbohydrates which alter 
their 1 ytic function. 
It is possible that the limited ability of LAK cells to extravasate could be 
modified. Migliori et al 1987 demonstrated that macrophage activation 
factor could effectively attract LAK cells from the circulation. By 
stimulation of macrophages at the sites of tumour growth, more LAK 
cells were attracted. Marincola et al 1988 found that when the nude 
mice were pretreated with human recombinant tumour necrosis factor 
{TNF), localisation of LAK cells was enhanced both in implanted 
tumours in the pancreas and in the surrounding normal tissue. 
The administration of IL-2 may be necessary to maintain the cytotoxic 
activity of injected LAK cells and their proliferation in v iv o 
(Ettinghausen et al 1985). Administration of IL-2 does not result in the 
accumulation of LAK cells at the site of IL-2 injection, nor did it result 
in a modulation of the overall distribution pattern or total recovery of 
radiolabelled LAK cells in organs (Maghazachi et al 1988c). The 
administration of IL-2 does not alter the anatomic distribution of A-
LAK cells when analyzed by tissue sections (Felgar et al 1990). 
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Harcel et al 1991 found that the frequency of LAI< cells localised in 
developing liver metastases was 3-6 times higher than that iri the 
surrounding normal liver tissue. Ames et al 1989 have shown that the 
preferential localisation of TIL in tumour sites to normal tissue. 
Griffith et al 1989 demonstrated that transferred human autologous 
TIL pretreated with IL-2 preferentially localised to metastatic tumour 
sites. They indicated that this localisation was based on the ability of 
TIL to distinguish tumour from normal tissue. LAI< cells showed 
increased migration to tumour site compared to splenocytes (Midis et 
al 1992). Morita et al 1987 found that the localisation of IL-2-activated 
PBL to hypernephroma was increased when these cells were given as 
an intra-operative, intra-arterial infusion just prior to nephrectomy. 
Hayakawa et al 1991, 1992 found that by transarterial regional infusion, 
LAK cells showed short-term but appreciable accumulation of LAK 
cells in the tumour site. 
There are several reports regarding the regional infusion of LAI< cells 
in tumour immunotherapy and in experimental systems. Keilholz et 
al 1992 showed that the regional administration of LAI< cells was 
essential for successful treatment. Tumour regression was observed 
only in anatomic areas of the liver into which the LAI< cells were 
locally perfused. Basse et al 199lb studied whether a more direct 
delivery of A-LAI< cells to the liver could enhance the uptake of A-
LAI< cells into the liver and improve infiltration of liver metastases. 
Using rhodamine-labeled A-LAK cells they found that after these cells 
were inoculated directly into the portal system, more than five times as 
many cells were found in the normal liver tissue compared to systemic 
iv. injection. By 16h, the number of A-LAI< cell in the normal liver 
tissue decreased whereas in tumour tissue the number was more than 
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5 times as many as after systemic iv. injection. These findings indicate 
that the route of injection is an important factor . in achieving 
accumulation of LAK cells within liver metastases. Conventional 
systemic iv. injection could be viewed as regional infusion for the 
lung. It is found that adoptively transferred cells reach the metastatic 
lesions in different organs in a time-dependent manner. 0-lh after 
injection, almost no infiltration of the metastases by A-LAK cells is 
seen. Many A-LAK cells are located at the nomal lung tissue at the 
begining, then disappear from nomal lung tissue at 16h whereas they 
are found in 90%-95% of pulmonary metastases. Kuppen et al 1992 
found that 2h after local infussion (through hepatic artery for liver and 
jugular vein for lungs), a high concentration of LAK cells in the first 
capillary bed can be obtained. They suggested that local administration 
of LAK cells may be more effective against tumour. Lafreniere et al 
1985 and Ettingha1:1sen et al 1985 have mentioned that the intraportal 
or intrahepatic administration of LAK cells is significantly more 
effective than the systemic iv. administration of these cells in 
treatment of liver metastases. Nelson et al 1990 also demonstrated that 
cultured human PBL distributed to intraperitoneal tumour when 
administered intraperitoneally, but did not do so when administered 
systemically intravenously. Basse et al 1992b found that a substantial 
accumulation of A-LAK cells in the liver could be achieved only when 
the cells were injected directly into the portal vein. 
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1.5 The Effect of Mannitol on the Blood Brain Barrier (BBB) 
In 1990 McCutcheon et al reported their investigation of adoptive 
immunotherapy for intracerebral metastases in mice. They 
demonstrated that intracerebral tumours are completely resistant to 
treatment with IL-2 and LAK cells. It has been demonstrated that after 
intravenous administration, LAK cells can migrate to some 
extracerebral tumour sites. The demonstration that intracerebral 
tumours were resistant to treatment with IL-2 and LAK cells suggests 
that the trafficking pattern of LAK cells may exclude them from the 
cerebral circulation, or that these cells are unable to breach the BBB. 
Takai et al 1988 reported controversial results suggesting intravenous 
or intracerebral injections of LAK cells resulted in longer survival of 
Fischer rats that had received inoculation of T9 gliosarcoma cells into 
the basal ganglia. Other experiments have failed to demonstrate an 
increased survival time in rodents with primary brain tumours treated 
with activated lymphocytes and IL-2. 
The BBB can be opened transiently in humans and in experimental 
animals by infusing a hydrophilic non-electrolyte hyperosmolar 
solution such as mannitol into the internal carotid circulation. 
Hiesiger et al 1986 investigated the effect of intracarotid infusion of 
hyperosmolar mannitol solutions on cerebral capillary permeability 
and blood flow. It was found that capillary sensitivity to osmotic 
manipulation is both tumour- and concentration-dependent. Before 
mannitol administration, the blood-to-tissue transfer constant (K) 
values in brain tumour sites were significantly higher than those in 
cortex. C6 gliomas were about three times more permeable than W256 
tumours. After the administration of 1.6M mannitol, the K values for 
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both tumours and adjacent tissue were increased. Groothuis et al 1990 
found that there was no change in the rate of delivery of cells to brain 
tumours as a result of hyperosmotic BBB disruption, however they 
found that there was a marked enhancement of delivery to tumour-
free brain. It was suggested that the reason is probably due to the type of 
tumour used for investigation (Rapoport et al 1990), i.e. the efficacy of 
hyperosmolar mannitol depends on the permeability characteristics of 
the tumor type. In addition there was a direct correlation between 
tumour size and increased capillary permeability. Mannitol at a 
concentration of l.37M did not increase the K values for either tumour 
or adjacent tissue. 
Osmotic shrinkge of cerebrovascular endothelial cells is generally 
considered to be the prodominant mechanism of BBB breakdown, 
resulting in passive diffusion across separated interendothelial cell 
junctions and enhanced endocytosis and vesicular transport across the 
endothelium (Houthoff et al 1982). Franceschini et al 1988 
demonstrated that treatment with hypertonic solutions of mannitol 
(0.25M, O.SM, lM) caused opening of the blood brain barrier in the newt 
due to the opening of the tight junctions between the endothelial cells, 
which was demonstrated by the presence of the tracer in 
interjunctional regions between adjacent endothlial cells. They found 
in the specimens treated with hyperosmolar mannitol that increasing 
the osmolarity of the solution caused more extensive disruption of the 
BBB. The molecular mechanisms mediating BBB breakdown in rats 
has been investigated by Koenig et al 1989. They reported that rapid 
stimulation of ornithine decarboxylase (a polyamines rate-regulating 
synthetic enzyme) activity and polyamine synthesis in cerebral 
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microvessels is involved in the breaching of the BBB by the 
intracarotid infusion of 1.6M hyperosmolar mannitol. 
36 
Chapter 2 Materials and Methods 
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2.1 Generation and Characterisation of A-LAK Cells 
A-LAK cells were generated according to the procedure described by 
Vujanovic et al in 1988. The characterisation of A-LAK cells was 
defined in three ways: (i). Cell surface marker analysis by 
immunofluorescent staining; (ii). morphological analysis by Giemsa-
stained cytocentrifuge preparations; (iii). cytotoxicity assay in a standard 
4h 51Cr-release microcytotoxicity assay. 
2.1.1 Generation of A-LAK cells 
Rats were obtained from the animal house of University of Tasmania. 
They were housed and kept in the animal room in the Clinical School 
in accordance with NH&MRC guidelines. Young male rats 100g-120g 
were used for splenectomy to obtain cells from spleen for cell culture. 
Syngeneic rats about 120g were used for the cell trafficking study. 
During the experiments, the rats were anaesthetised with inhalation of 
ether combined with ip. injection of 1:10 diluted pentobarbitone 
sodium (Boehringer Ingelheim, Australia). For the inhalation 
anaesthesia, the rat was placed into a glass box containing with Sml-
lOml ether and kept there until it's whiskers stoped moving. Usually 
the rat could wake up in 1-Smin without continuous inhalation of 
further ether or ip. injection of pentobarbitone. The Pentobarbitone 
sodium(60mg/ml) was diluted with PBS-A which was sterilised by 
filtration (0.22µ filter, millipore Corporation, USA) in the ratio of 1:10. 
The diluted pentobarbitone was atored at 4-8°C. Before it was injected 
intraperitoneally into the rat, the dose was determined by the weight of 
the rat and administered at 30mg/kg (eg. O.Sml for a lOOg rat). This 
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combined anaesthesia method gave a satisfactory result which usually 
lasted for more than 30min. 
Dose of Pentobarbitone Na used in the experiments (ip.) 
minimum Volume of Maximum Volume of 
weight of rats body 1:10 Pentobarbitone 1:10 Pentobarbitone 
Na Na 
lOOg O.Sml O.Sml 
llOg O.Sml O.SSml 
120g O.Sml 0.60ml 
130g 0.Sml 0.65ml 
140g O.Sml 0.70ml 
lSOg O.Sml 0.75ml 
Under the anaesthesia, laparotomy was carried out aseptically using 
standard procedures (Van Dongen et al 1990). All the operative 
instruments were autoclaved at 120°C for lSmin and dried for 20min 
in the autoclave machine. Rat skin was prepared with 70% ethanol and 
the abdomen was opened through the midline. After the spleen or 
mesenteric lymph nodes were removed, the abdomen was closed using 
4-0 absorbable suture and the skin edges were brought together and 
secured with clips. Rats which underwent splenectomy were sacrificed 
by neck spine dislocation immediately after operation and under full 
anaesthesia. 
Each rat spleen was placed into RPMI-1640 (Flow, UK.) in a sterile petri 
dish in a laminar flow hood to perform the procedure of lymphocyte 
preparation. Each spleen was gently squashed and single-cell 
suspensions were obtained, washed in RPMI 1640 three times to 
remove cell debris (at 250g for 5-lOmin). Cells were resuspended in 6ml 
of Tissue Culture Medium (TCM) which consisted of RPMI 1640 with 
10% FCS (Flow, UK.). Splenic _mononuclear cells were isolated after 
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centrifugation of splenocytes on Ficoll-Hypaque gradients (Flow, UK, 
density l.077g/ml, at 300g for 20min). 
To deplete B cells and macrophages, these mononuclear cells were 
incubated in a nylon wool column (Julius et al 1973). The nylon wool 
(Polysciences, Inc., US.) was previously soaked extensively in 0.9% 
saline for one week to remove toxic substances. The nylon wool 
column (20ml syringe containing 0.6g of sterile nylon wool) had been 
incubated with 15ml warm TCM in 37°C for lh. 0.5xl08 to l.Ox108 cells 
in 1-2ml were incubated on the columns at 37°C for lh. Nylon wool 
non-adherent lymphocytes were collected by gently washing the 
column through with 20ml-30ml warm TCM. 
For A-LAI< cell generation, 10-20ml nylon wool nonadherent 
lymphocytes at a density of 2.0-3.Sx106 cells/ml were cultured in 
Complete Medium [CM: RPMI 1640 medium (Flow, UK.) 
supplemented with 10% heat-inactivated FCS (Flow, UK.), 2mM L-
glutamine (Flow, UK.), 50µg/ml streptomycin and 100 U/ml penicillin 
and 1 % nonessential amino acids (Flow, UK), Hepes buffer (CSL, 
Australia), 2-Mercaptoethanol (7x10-4 M) and 1000 U /ml human rIL-2 
(Boehringer Mannheim, W.Germany)] in 75cm2 tissue culture flasks 
(Corning, US.) using the method described by Vujanovic et al 1989. 
The cells were cultured in a humidified atmosphere of 5% C02/95% air 
at 37°C. After culture with rIL-2, some LGL selectively adhered to the 
plastic surface of the culture flask. At 48h of culture, the nonadherent 
cells were decanted from the flask, removed by centrifugation, and the 
medium passed through a 0.45-µm millipore filter (Flow, UK). In this 
way the conditioned medium was retained. After washing the flask 
with warm TCM to clear away the nonadherent cells, the conditioned 
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medium was added back to the adherent LGL cells in the flask. The 
adherent cells were then cultured in the pure conditioned medium or 
in conditioned medium diluted with fresh CM for several more day!:! 
till the adherent LGL had undergone adequate expansion. 
A-LAK cells were harvested after adding Sml cold SmM EDTA (BDH, 
UK.) in PBS to the culture flask. Then cells were washed in RPMI-1640 
and resuspended in RPMI 1640 + 10%FCS. Cell viability was assessed by 
trypan-blue dye exclusion. When cell viability was less than 90%, the 
cells were centrifuged on Ficoll-Hypaque gradients (density=l.077 g/ml, 
Pharmacia, USA; 400g for 30min) to remove the dead cells. The viable 
cells were collected, washed and resuspended in medium for radio-
labelling or cell characterisation. 
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2.1.2 Characterisation of A-LAK cells 
2.1.2a Cell surface marker analysis 
Cell surface marker analysis was carried out using immunofluorescent 
staining. A-LAK cell surface phenotype has been discussed in section 
1.3.2. The monoclonal antibodies (Mab's) used for A-LAK cell surface 
marker analysis in this experiment were: 
OXs: a murine IgGl for the surface marker of CDs on rat NK cells, LAK 
cells, T suppressor/cytotoxic lymphocytes; OX19: murine IgGl for the 
surface marker of CDs on rat pan-T cells; OX34: murine IgG2a for the 
surface marker of CD2; OX1: murine IgGl for rat leucocyte common 
antigen. These Mab's were obtained from Serotec, Australia. The 
second-step reagent was sheep-antimouse IgG F(ab')2 fragment 
conjugated with FITC (Silenus, Australia); Sheep anti-rat 
immunoglobulin antibody (Silenus, Australia) conjugated with FITC 
were used for rat B cells; Mouse IgGl conjugated with FITC (Becton 
Dickinson, US.) were used as negative controls. 
Chambers et al 1989 introduced a more specific Mab for rat A-LAK cells 
and NK cells named 3.2.3 antibody, an IgGlk (CD16). This Mab was not 
available in Australia when cell surface marker analysis was 
performed in this study. 
The Mab's were stored at -20°C. When used in immunofluorescent 
staining, lµl of each of these undiluted antibodies or 10µ1 of 1:10 
freshly diluted antibodies with PBS + 0.5%BSA were mixed with 1.0-
2.0xlos cells in 100µ1 staining buffer. 
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For surface marker analysis, nylon wool nonadherent lymphocytes or 
A-LAK cells from culture were washed for 3 times in cold PBS-A 
(phosphate buffered saline; Oxoid limited, UK) and once in staining 
buffer. The staining buffer comprised PBS-A, 0.1%sodium azide (BDH, 
UK) and 20% bovine serum albumin (CSL, Australia). Then 1.0-2.0xlos 
lymphocytes or A-LAK cells in 12x75-mm plastic tubes in 100µ1 cold 
staining buffer were mixed with 10µ1 of primary Mab's (1:10) at 4°C for 
45-60min. The cells were washed three times in staining buffer and 
resuspended with 10µ1 of the second antibody and kept at 4°C for 
30min. After three further washes the cells were resuspen~ed in 10µ1 
staining buffer and put on glass slides (Knittel Glaser, Germany). They 
were fixed in 100% Ethanol after dried on slides at room temperature. 
20µ1 PBS-Azide-Glycerol (Heidelberg, US) was added and cells were 
covered by a glass cover slip. Cells were counted using alternate 
incidental or UV light. 
2.1.2b Morphological analysis 
Giemsa-staining cytocentrifuge preparations were made using of 2.0-
4.0xlOS cells in 200µ1 to analyse cell morphology. Cells were washed in 
PBS twice and resuspended in PBS + 10%FCS at l.0-2.0xl06 cells/ml. 
Each slide was made using 200µ1 (2.0-4.0xlOS cells). Cytocentrifuge 
holders were washed in sterilised water and kept dry before use. Special 
filter cards (Shandon, UK) together with slides and holders were placed 
into the cytocentrifuge and the cells were added into the holders. After 
centrifugation at lOOOrpm for 3min, the cells were dried on the slides at 
room temperature. Giemsa stain (BDH, UK) was used at 100% density 
or diluted 1:1 with PBS to stain the cells on slides for Smin. The slides 
were rinsed with PBS, dried at room temperature and fixed under 
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cover slips. The cells were examined using a Lietz Ortheplan 
microscope and photographic records were made. 
2.1.2c Cytotoxicity assay 
Cytotoxicity was measured using a standard 4h 51Cr-release 
microcytotoxicity assay carried out in 96-well, round-bottomed micro-
well plates (Coming, USA). Target cells were YAC-1 and P815. YAC-1, a 
mouse T cell lymphoma, was used as an NK-sensitive target. P815, a 
murine mastocytoma, was used as an NK-resistant target cells. Target 
cells were kept in culture medium (RPMI 1640 with 10%FCS, SOµg/ml 
streptomycin and SOU/ml penicillin, 2mM L-glutamine and HEPES 
buffer) at 37°C and subcultured 2-3 times per week. Target cells were 
harvested from the culture when they were needed for cytotoxicity 
assays. l.0-2.0xlQ6 target cells were labelled with lOOµCi of 51Cr at 37°C 
for lh, washed, resuspended in RPMI-1640 at a concentration of 5.0xlQ4 
cells/ml, and seeded into 96-well round-bottomed microplates at 5x1Q3 
cells/well. Effector cells were harvested from A-LAK cell cultures, 
washed and resuspended in RPMI 1640 + 10%FCS at concentrations of 
2.0x1Q6 cells/ml, S.OxlQS cells/ml, and 1.25x1Q5 cells/ml. A-LAK cells 
were added to microwells to give effector: target ratios of 40:1, 10:1 and 
2.5:1 in a final volume of 200µ1 per well. Each ratio was set up in 
triplicate. After 4h incubation at 37°C, 100µ1 of supernatant was 
collected from each well and was counted in a gamma counter to 
determine experimental release. Spontaneous release and maximum 
release were also measured. Spontaneous release was obtained from 
wells receiving target cells only. Maximum release was obtained from 
target cells to which 1 % Triton X-100 (BDH, US) was added to cause 
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complete cell lysis. Percentage cytotoxicity was calculated using the 
formula: 
% cytotoxicity = 100 x experimental release - spontaneous release 
maximum release - spontaneous release 
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2.2 Short-term in Vivo Distribution of Radiolabelled A-LAK 
Cells in the Rat 
.2.2.1 Radiolabelling of A-LAK cells 
A-LAK cells harvested from culture were labelled with 51Cr. After 
suspending l-9xl06 cells in lml RPMI 1640 + 10%FCS, lOOµCi 51Cr was 
added and the cells were incubated at 37°C in a water bath for lh. The 
radiolabelled A-LAK cells were washed in RPMI-1640 5 times. 50µ1 of 
supernatant of the first, 4th and last washing were taken for gamma-
counting to ensure that there was no free 51Cr remaining in the 
supernatant. After labelling, A-LAK cells were resuspended in serum-
free PBS-A, and cell viability was checked by trypan blue exclusion 
before infusion. 
Radiolabelled A-LAK cells were suspended in l.2ml PBS-A. lml 
labelled A-LAK cells were placed in a 2ml-syringe for infusion into rats 
for the trafficking study. Three aliquots of 25µ1 labelled cells were taken 
at the same concentration as the injected cells and counted on gamma-
counter. The radioactivity (cpm) in the total volume of infused cells 
was obtained by correcting the cpm obtained from 25µ1 labelled cells to 
the total injected cell volume. (total injected cpm in lml= 40 x cpm in 
25µ1). The remaining labelled cells were used to check the spontaneous 
release of 51Cr from the cells. These remaining cells were resuspended 
in 300µ1 RPMI 1640 + 10%FCS and put separately into three tubes 
(100µ1 for each tube). After centrifugation at lOOOrpm for 3min, cells 
were incubated at 37°C in 5%C02/95% air for 2h. The radioactivity in 
1/2 supernatant (50µ1) and in l/2supernatant+pellet was counted using 
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a gamma-counter. Spontaneous release (SR) was calculated using the 
formula: 
%SR= 2 x cpm in 1 /2 supernatant x 100 
cpm in 1/2 supernatant+ cpm in (1/2supernatant+pellet) 
Because the 51Cr may also be released from the injected cells in vivo, 
the total injected cpm measured before infusion could no longer reflect 
the CPM of injected cells in 2h. Therefore the CPM of A-LAK cells after 
2h was obtained using the formula: 
CPM of injected cells in 2h = total injected cpm x (1-%SR). 
2.2.2 Adoptive transfer of radiolabelled A-LAK cells 
into recipient syngeneic rats 
Trafficking studies were carried out in three groups (eight rats per 
group). One milliliter of radiolabelled A-LAK cells was infused into 
each rat. In group (1), A-LAK cells were systemically injected through 
the tail vein. In group (2), A-LAK cells were regionally injected 
through the portal vein. In group (3), A-LAK cells were injected 
through the portal vein following intraportal infusion of 30% 
mannitol. 
For the injection of 51Cr-labelled A-LAK cells, each rat was 
anaesthetised with inhalation of ether and ip. injection of 
pentobarbitone sodium as described in section 2.1.1. A 27gar needle 
(Terumo, Melbourne, Australia) was used for cell injection through 
the tail vein. The rat was then kept in its cage for 2h. For regional 
infusion, laparotomy was carried out aseptically, the portal vein was 
exposed, a PElD cannula was inserted and the cells were infused under 
observation. When the cannula was removed, the small hole in the 
47 
portal vein was compressed for 1-Smin to prevent bleeding. The rat's 
abdomen was closed and rat was kept in its cage for 2h. . 
This study was initially planed to inject cells through hepatic artery not 
the portal vein. Unfourtunitely it appeared impossible due to techn,ical 
difficulties with PElO cannula which was the smallest cannula that 
could be connected to a 27gar needle(smallist available). We realised 
that the hepatic metastases are via the hepatic arterial but not the 
portal vein. However with the aim of studing the effect of mannitol on 
the distribution of LAK cell in tissue level in the no tumour-bearing 
organs, the potal vein infussion should be able to lead us to obtain the 
close results about the cell distribution as it would show via hepatic 
artery. 
2.2.3 Determination of tissue distribution of 
radiolabelled A-LAK cells 
Two hours after A-LAK cell infusion, the rats were sacrificed by 
inhalation of an overdose of ether. A blood sample was taken by heart 
puncture and 3 MLN, the spleen, both kidneys, liver, lung and brain 
were removed and each organ was weighed. The radioactivity 
associated with liver, lung and brain samples were determined by 
counting weighed pieces of each organ and then correcting counts for 
the total weight of each organ. The radioactivity associated with the 
other organs were determined by counting the whole organ. Blood-
associated radioactivity was normalised to a total volume of lOml per 
rat. Results of the distribution of A-LAK cells were expressed as ,a 
percentage of injected CPM in organs. They were also expressed as 
percentage of radioactivity in every gram of organ which was 
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specifically used for representing the distribution of A-LAK cells in 
different tissues without the influence of the organ size .. 
Of d" "b . f LAK 11 . CPM in that organ xlOO 
10 1stn ution o ce s m organ= 
CPM in organ= cpm of piece of organ 
%counted 
CPM of all cells 
%counted= weight of counted piece xlOO 
weight of whole organ 
%distribution of LAK cells per gram of organ= %distribution in organ 
weight of organ 
2.3 Administration of Mannitol 
Sterile 30% (0.03 g/ dl) Mannitol (Multicel, Australia) at the dose of 
0.3mg/kg body weight (100µ1/lOOg) was infused into the portal vein 
Smin before the A-LAK cell injection. 
To study the effect of intraportal mannitol on the distribution of A-
LAK cells in the rat, the distribution of intraportally infused A-LAK 
cells after the mannitol was compared with that of intraportal A-LAK 
cells without mannitol. Thirty% mannitol instead of 20% mannitol 
was used in this study because it had been demonstrated that the 
higher osmolal solution had a greater effect in increasing the space 
between vascular endothelial cells (Franceschini et al 1988). At 
concentration of less than 20%, mannitol had no obvious effect in 
opening the Blood-Brain Barrier (Hiesiger et al 1986). The A-LAK cells 
were infused through the portal vein cannula Smin after the mannitol 
injection because it had been shown in these studies that the effect of 
mannitol commenced after S-30min. 
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For the administration of mannitol and A-LAK cells, laparotomy was 
carried out aseptically. The portal vein was well expo~ed and a PE10 
cannula was inserted. The 30% mannitol was previously warmed in a 
37°C water bath to dissolve all the crystals in the mannitol solution. 
Following the administration of mannitol, lml radiolabelled A-LAK 
cells was infused under observation. The rat was kept in its cage for 2h. 
The rats were sacrificed, organs were harvested and CPM in organs 
were determined as per Section 2.2.3. 
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Chapter 3 Results 
3.1 A-LAK Cell Generation and Characterisation 
3.1.1 Isolation of A-LAI< precursor from spleen mononuclear 
cells 
To study the distribution of A-LAI< cells following infusion into the rat 
it was necessary to obtain the purest possible culture of A-LAK cells as 
possible. The isolation of LGL was carried out in two stages: firstly by 
incubation of spleen mononuclear cells in a nylon wool column to 
eliminate Macrophages and B cells; and secondly by removal of flask 
non-adherent T cells from the culture flask. The number of 
mononuclear cells obtained from the spleen following centrifugation 
on Ficoll-Hypaque (p=l.077) ranged between 6.7xl07 and 17xl07 cells. 
These cells were a mixed population including T cells, B cells and 
Microphages, which were shown in Fig. A. Following nylon wool 
incubation cell numbers ranged between 2.7xl07 and 7xl07 cells. The 
mean percentage of cells removed on NW-colum'n was 57.9%±14.5%. 
These nylon-wool nonadherent lymphocytes are shown in Fig. B. 
After 48h of cell culture the culture flask was washed gently. The cell 
population present in the washing were termed flask non-adherent 
cells. 
Immunofluorescent staining was only possible on a small number of 
samples. The results are shown in Table 1. The results indicated that 
the incubation of lymphocytes on nylon wool columns resulted in a 
modest reduction of B cells in the nylon wool non-adherent cells, and 
the presence of significant number of OX34 and OXg cells in the nylon 
wool non-adherent population. Immunofluorescent staining of the 
flask-nonadherent cells following 4Bh.of culture showed that majority 
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of the population were T cells and B cells. These results indicated that 
the reductions of B and T cells were suitable to allow .the culture of 
flask adherent LGL/LAK cells. 
Table 1 Cell surface marker analyses of NW-nonadherent lymphocytes 
and the flask-nonadherent cells from 2-days culture 
Cells OXl 2ndAb Mouselg Slg OX19 OX34 oxs 
G 
NW-na 100% 8% 0% 36% NT NT NT 
NW-na 100% 4% 0% 35% 50% 83% 50% 
NW-na 100% 4% 0% 12% 60% 63% NT 
100µ1 of 1-2x106 /ml NW-nonadherent lymphocytes' surface marker were analysed 
by immunofluorescent staining. Slg is for B cells. OX19 is a pan T cell marker. OX34 
and OX8 are shared by LGL/NK cells and T cells. 
NT- non-tested. 
3.1.2 Second antibodies 
The immunofluorescent staining method, sheep-antimouse IgG 
F(ab')z fragment conjugated with FITC was used as the 2nd-Antibody. 
Unlike sheep anti-rat immunoglobulin antibody (for rat B cells) and 
Mouse IgGl (for negative controls), the primer Mab's used in this study 
are not conjugated with FITC. To make the cells visible under UV 
microscope it is essential to stain the 2nd-Antibody on the primer 
Mab's on cells. The 2nd-Antibody should only combine with primer 
Mab's. Table 1 shows that there was a low rate of nonspecific reaction 
of the 2nd-Antibody with cells. By preincubating the cells in 20% BSA 
in 37°C water bath for 30min to decrease the possibility of the cell 
membrane changing, increasing the cell viability up to nearly 100%, 
and keeping cells in 4°C temperature during the procedure, diluting 
the 2nd-antibody before using, it was not possible to further decrease 
the nonspecific reaction of this 2nd-Antibody with cells. Finally by 
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incubation of 2nd-Antibody with fresh lymphocytes, the 2nd-Antibody 
had no nonspecific reaction with A-LAK cells as shown in Table 2: 
3.1.3 Culture of A-LAK cells 
A-LAK. cells were generated by culturing nylon wool nonadherent 
lymphocytes with IL-2. Initially 5-lOml of 2xl06 cells/ml NW-
nonadherent cells were cultured in 25cm2 small culture flasks with 
lOOOU /ml IL-2. However, after several experiments it was found that 
cultures grew better in 75cm2 culture flasks using 10-20ml of 2xl06 to 
3.Sxl06 cells/ml. In final experiments, the A-LAK cell cultures were 
started with up to 4x1Q6 cells/ml. 
During the first 2 days of culture, LGLs adhered to the plastic surface of 
the culture flask. The number of adherent LGL in the flask after 
removing flask nonadherent cells was not investigated. We did not 
collect adherent LGL from flasks for cell counting. However after the 
flask-nonadherent cells had been decanted, the adherent cells were 
evaluated by observing the frequency of adherent cells in the flasks 
under microscopy. The number of adherent cells generated varied 
from rat to rat. It was shown that the viability of flask-non-adherent 
cells varied widely from culture to culture. Low cell viability usually 
indicated that the culture was not successful, and was usually followed 
by a failure of LGL proliferation. 
The adherent LGLs were continuously cultured in the culture flask as 
shown in Fig. C. In this study, 3-10 days more were needed to obtain 
adequate expansion of A-LAK cells. The number of A-LAK cells 
harvested varied between. lxl06 . and 8.8xl06 cells. One interesting 
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observation was that the cells in the culture flask always proliferated 
well in one area (mostly in the middle of the flask and slowly in the 
surrounding area). When the cells in the middle of the flask became 
fully expanded, those cells in the other area of the flask had not fully 
expanded. This presented a significant problem of A-LAI< cell 
generation in this study. 
The culture medium used for continuing the adherent LGL 
proliferation was conditioned medium or a mixture of fresh medium 
with conditioned medium. It was found that using fresh medium only 
instead of conditioned medium to continue the culture resulted in a 
slow proliferation of LAK cells. Thus conditioned medium was usually 
used. However, when there were many dead flask nonadherent cells in 
supernatant after first 2-days culture, it was necessary to use fresh 
medium to obtain a better growth of cells. Using conditioned medium 
could result in failure of cell proliferation in this situation. Adding 
fresh medium to the conditioned medium could result in a more 
satisfactory proliferation of these adherent cells. The final methodology 
for this study was to continue the adherent LGL culture with a mixture 
of conditioned medium and fresh medium. A-LAI< cells harvested 
from these cultures usually comprised about 5xl06 cells. 
3.1.4 Identification of A-LAK cells 
To confirm that the cells from this culture were A-LAK cells, three cell 
characterisation methods were used. 
i) Immunofluorescent staining of cell surface markers using Mab's 
OXs for the LAI< cells and OX19 as a pan-T cells marker to exclude the 
possibility that these OXs positive· ~elis were T cells. NK cells and A-
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LAK cells do not express the T cell surface marker of CDs (which react 
with OX19). Sixty seven per cent to 90% of A-LAI< cells showed the 
surface marker phenotype of NK/LGL cells (OXB) (Table 2). The 
population contained few pan-T positive cells (only 4-6.5% of cells 
expressing OX19). No B cell surface marker lg was detectable in the A-
LAK cell population. 
Table 2 Cell surface marker analyses of A-LAK cells 
Cells OXl 2nd-Ab Mouseig Sig OX8 OX34 OX19 
G 
A-LAK 100% 5% 0% 0% 76% 60% NT 
A-LAK 100% 0% 0% 0% 90% 50% NT 
A-LAK 100% 0% 0% 0% NT 78.4% 4.4% 
A-LAK 100% 0% 0% 0% 67% 28% 6.5% 
100µ1of1.5-Sx106 /ml A-LAK cells were used for analysing of their surface phenotype. 
10µ1 Mabs were added into the cells and incubated in 4°C for 60min. After being washed 
in cold PBS-20%BSA-O.l %Azide, 10µ1 of 2nd-Ab were added and incubated in 4°C for 
30min. After washing extensively with the same staining buffer, cells in 10µ1 same 
bufferwereputon slides and dry in room temperature. Then the cells were fixed with 
100% Ethanol. Cells were counted on UV microscope after covered with slip. 
ii) Morphological identification of A-LAK cells was carried out to 
further confirm the immunofluorescent staining results. Fig. D shows 
morphological analysis of A-LAK cells using Giemsa-stained 
- cytocentrifuge preparations. Purified A-LAK cells were 
morphologically large granular lymphocytes (LGL). The A-LAK cells 
have relatively high cytoplasmic/nuclear ratio (because of abundant 
cytoplasm), eccentric reniform nucleus, prominent cytoplasmic 
granules and undulating surface. 
iii) Cytotoxicity assays were carried out to confirm the functional 
integrity of A-LAK cells. A-LAK cells showed high ability to lyse 
cultured YAC-1 (a mouse T cell lymphoma, was used as an NK-
sensitive target) and P-815 (a murine mastocytoma, was used as an NK-
resistant target) cells in 4h 51Cr~reiease 'cytotoxic assays. In this study, A-
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LAI< cells lysed 33-40% YAC-1 cells and 44-52% P815 cells at the E/T 
(effector to target) ratio of 10:1. At an E/T ratio of 40:1 A-LAI< cells lysed 
70% P815 cells and 100% YAC-1 cells. 
A-LAK: YAC-1 A-LAK:P815 
2.5 :1 10:1 40:1 2.5:1 10:1 40:1 
15.1% 40.4% ND 2.9% 52.5% ND 
13% 33% ND 17% 44% ND 
14.05% 36.7% 101% 9.95% 48.25% 70% 
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3.2 A-LAK Cell Distribution 
3.2.1 51Cr labelling of A-LAK cells 
In this study the A-LAK cell distribution was investigated by counting 
the radioactivity accumulated in organs after radiolabelled A-LAK cells 
were infused. A-LAK cells were radiolabelled with 51Cr before 
infusion. 
To ensure that the cells infused into the rat were free of free 51Cr 
isotope, cells were washed 5 times with PBS-A following labelling. This 
technique proved to be effective in removing free 51Cr (Table 3). The 
radioactivity in the supernatant was negligible compared to that of the 
cells (0.9-7.0% of that in cells). 
The efficiency of cell labelling was 0.002-0.018 cpm/ cell (Table 4). This 
level of radioactivity was sufficient for studying the distribution of A-
LAK cells. in tissues after cell injection. 
Spontaneous release of 51Cr from cells after 2h incubation at 37°C was 
studied. This is required to show the degree of spontan~ous leakage of 
radioactivity from cells after infusion, in order to obtain the true 
radioactivity within A-LAK cells in each organ. Table 4 shows that the 
SR% varied from 8.6%-56.0% with mean result of 30.8%±15.5%. In this 
table "CPM of cells" refers to radioactivity which is estimated to remain 
within A-LAK cells in vivo 2h after infusion (ie after subtraction of 
spontaneous release). 
The viability of infused ~ells was u~ually >90%. 
- ~- .. 
. . 
-
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Table 3 Radioactivity in supernatant and in A-LAK cells 
Group 1 cpm in 50µ1 lst cpm in 50µ1 last ~min free51cr I washing supernant washing supernatant Jµl cells cpmincells 
rat 1 1453 23.5 571 4.1% 
rat 2 3037 17.2 560 3.1% 
rat3 891 110# 245 -
rat4 3114 42.4 928 4.6% 
rat 5 470 8 206 3.9% 
rat 6 613 16 498 3.2% 
rat 7 952 17 680 2.5% 
rat 8 1105 54 748 7.2% 
Group2 
rat 1 3975 20 368 5.4% 
rat 2 29059 703* 936 -
rat 3 962 19.8 432 4.6% 
rat4 3000 37 1596 2.3% 
rat 5 404 20 540 3.7% 
rat 6 952 17 680 2.5% 
rat 7 1105 54 748 7.2% 
rat 8 1105 54 748 7.2% 
Group3 
rat 1 3330 26.1 904 2.9% 
rat 2 2939 31 862 3.6% 
rat 3 2504 32.3 792 4.1% 
rat4 3114 42.4 928 4.6% 
rat 5 470 8 206 3.9% 
rat 6 941 4 431 0.9% 
rat 7 941 4 431 0.9% 
rat 8 951 11 378 2.9% 
After labelling with lOOµCi 51Cr in a 37°C water bath for lh, cells were washed in PBS 
for 5 times to clean out the free 51Cr in the supernatant. 
#showed the result from 4th washing. cells were washed once again and resuspended in 
lml PBS for infusion. (The radioactivity in 4th washing supernatant were usually 140-
401 for other labelling. Results are not shown in this table) 
*It is the radioactivity in the 4th washing supernatant. Cells were then washed twice 
more. Last time washing was not taken out for counting. 
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Table 4 A-LAK cell labelling, and spontaneous release of 51Cr 4l 2h 
Group LAKcells Total cpm Radioactiv SR%of CPMof 
Group 1 infused in cells ity cpm cells# 
infused cpm/cell in 2h 
rat 1 0.66x106 3428 0.0052 37% 2160 
(0.3ml) 
rat 2 2.64 x 106 22400 0.0085 56% 9856 
(2ml) 
rat 3 2.1 x 106 4896 0.0023 8.6% 4475 
rat4 1.5 x 106 18552 0.0124 42% 10760 
rat 5 1.7 x 106 4116 0.0024 14.5% 3519 
rat 6 1.65 x 106 9970 0.0060 16% 8376 
rat 7 1.5 x 106 13598 0.0091 10.7% 12143 
rat 8 2.5 x 106 14956 0.0060 45% 8226 
Group 2 
rat 1 0.85 x 106 7364 0.0087 43.6% 4153 
rat2 3.5 x 106 18720 0.0054 55% 8424 
rat 3 2.8 x 106 8640 0.0031 18.9% 7007 
rat4 1.6 x 106 28728 0.018 17.2% 23787 
(900µ1) 
rat 5 1 x 106 10793 0.0108 28.5% 7718 
rat 6 1.5 x 106 13598 0.0091 10.7% 12134 
rat 7 2.5 x 106 14956 0.0060 45% 8226 
rat 8 2.5 x 106 14956 0.0060 45% 8226 
Group 3 
rat 1 1.02 x 106 18080-883* 0.0177 29% 12210 
rat 2 2.86 x 106 17248 0.0060 56% 7589 
rat3 1.44 xl06 12675- 0.0088 35% 7038 
(800µ1) 1848* 
rat 4 1.5 x 106 18552 0.0124 42% 10760 
rat 5 1.7 x 106 4116 0.0024 14.5% 3519 
rat6 2.9 x 106 8612 0.0030 25.6% 6407 
rat 7 2.9 x 106 8612 0.0030 25.6% 6407 
rat 8 1.6 x 106 7552 0.0047 18.6% 6147 
#CPM in cells represented the radioactivity in cells after incubated in rat for two 
hours. It is obtained after subtracted the SR% from the radioactivity of the infused 
cells. 
*this radioactivity was obtained from the cells which were not infused into the portal 
vein because of leakage. They were soaked in cotton wool and the radioactivity of 
them was counted. 
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3.2.2 Distribution of A-LAK cells by systemic and 
regional infusion and their comparison 
To study the distribution of A-LAK cells in organs by systemic and 
regional infusion, l.0-3.5xl06 labelled A-LAK cells in lml PBS were 
infused into syngeneic male rats through the tail vein or portal vein 
respectively. Both groups comprised 8 rats for the trafficking studies. 
Two hours after A-LAK cell infusion, rats were sacrificed and the 
organs (spleen, kidney, lung, liver, MLN, brain) and blood were taken 
for gamma-counting to study the distribution of the labelled A-LAK 
cells in these organs. 
The distribution of A-LAK cells after 2h is shown in Table 5 and Figure 
2, and in Table 6 and Figure 3. Table 5 show~ the mean result of 
labelled cell distribution per organ via systemic and regional infusion 
and the comparison between the two groups. (The cell distribution in 
each individual rat is shown in Table Din the Appendix). As shown in 
Table 5, there was no significant increase in the A-LAK cell distribution 
to the liver by regional infusion compared to systemic infusion. There 
is a suggestion of increased early accumulation of A-LAK cells in the 
liver following portal vein infusion (24.36% vs 16.41 %) however this 
result is not statistically significant (P>0.05, Student's t-test). Following 
regional infusion, fewer cells accumulated in the lungs (6.01% vs 
15.65%, P<0.05) compared with systemic infusion. The distribution of 
A-LAK cells to the brain was very small by either systemic or regional 
infusion (0.12% and 0.08% respectively). 
Table 6 shows the mean result of A-LAK cell distribution expressed per 
_ gram of organ, comparing ~yst~n:ii~.to.regional infusion. Calculation of 
the results in this way should give a more accurate representation of 
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cell distribution because it excludes variation which could result from 
the different size of organs between rats. These results also show· that 
there was no significant increase in the A-LAK cell distribution to the 
liver by regional infusion compared to systemic infusion. The results 
are suggestive of greater distribution of A-LAK cells into liver by 
regional infusion through portal vein (3.89%/ g vs 2.15%/ g) however 
the result is not of statistical significance. In lung the increased early 
distribution of A-LAK cells which resulted from systemic infusion 
through tail vein compared to portal vein was again shown {19.02%/ g 
vs 6.55%/ g, P<0.05, Student's t-test). There was no significant difference 
in cell distribution per gram in spleen, kidneys and brain by these two 
routes of infusion. The distribution of A-LAK cells to brain could be 
neglected on the basis of per gram of tissue. By showing the cell 
distribution per gram of MLN, it is shown that there was distribution 
of A-LAK cells to MLN, however there was no significant difference 
between systemic and regional portal Infusion. 
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Table 5 Comparison of A-LAK cell distribution per organ 
by systemic and regional infusion 
ORGAN SYSTEMIC REGIONAL P** 
%DI organ* ± sd %D/organ* ± sd 
blood 2.71 ± 1.23 3.66 ±3.24 0.45 
spleen 1.51 ± 1.21 0.97 ±0.80 0.31 
kidneys 1.57 ±0.66 1.78 ±2.24 0.8 
MLN 0.04 ±0.03 0.02 ±0.02 0.18 
lung 15.65 ± 11.43 6.01 ±5.9 0.05 
liver 16.41 ± 11.56 24.36 ±11.5 0.19 
brain 0.12 ±0.14 0.08 ±0.11 0.53 
*%D/organ= mean percentage of total dose of A-LAK cells infused, taking into accout of 
spontaneous isotope release, per whole organ (8 rats). 
**P- Student's t-test. 
Figure 2: Graphical representation of data from Table 5 
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Table 6 Comparison of A-LAK cell distribution per gram 
by systemic and regional infusion 
ORGAN SYSTEMIC REGIONAL P** 
%D/g*±sd %D/g*±sd 
spleen 2.77 ± 1.76 2.23 ± 1.92 0.56 
kidney 1.18 ±0.65 1.19 ± 1.03 0.99 
MLN 1.72 ± 1.16 1.7 ± 1.9 0.98 
lung 19.02 ± 14.27 6.55 ±4.31 0.03 
liver 2.15 ± 1.71 3.89 ±2.52 0.13 
brain 0.1 ±0.11 0.06 ±0.09 0.51 
*%DI g = mean percentage of total dose of A-LAK cells infused, taking into account of 
spontaneous isotope release, per gram of organ (8 rats). 
**P- Student's t-test 
Figure 3: Graphical representation of data from Table 6 
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Figures 4 and 5 give a graphical representation of the distribution of 
labelled A-LAK cells per gram of tissues. These calculations are based 
on the assumption that little radioactivity accumulated elsewhere, ie. 
in organs not tested, such as muscle, soft-tissue and gut. The whole 
radioactivity in these tissues is taken as 100%. Because some A-LAK 
cells must have distributed to these non-tested sites, these graphs can 
be taken as close approximation of the A-LAK distribution at 2 hours to 
these tissues. Taking account of this assumption, approximately 70% of 
radioactivity was recovered in lung, which was 9 times of that in liver 
tissue following systemic infusion (Figure 4). The tissue distribution by 
systemic infusion was in the order of: lung> spleen> liver> MLN > 
kidney> brain. In Figure 5 it is shown that by portal vein regional 
infusion the radioactivity recovered in lung was approximately 40% of 
the total recovered activity in detected organs. Following portal vein 
infusion lung tissue retained about twice the activity of liver tissue. 
Liver tissue was second in order of tissue uptake of labelled A-LAK 
cells, compared to other tissues following regional infusion. 
These results show that regional infusion increased the distribution of 
cells to liver and decreased the early accumulation of cells in lung. 
However irrespective of the route of infusion, the highest cell uptake 
was in lung tissue. 
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Figure 4: Graphical representation of the distribution of A-LAK 
cells per gram in detected organs by systemic infusion. 
• spleen 10.3% 
S! kidney 4.4% 
• MLN 6.4% 
[J lung 70.6% 
• liver 8.0% 
EEi brain 0.4% 
Figure 5: Graphical representation of the distribution of A-LAK 
cells per gram in detected organs by regional infusion. 
• spleen 14.3% 
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• MLN 10.9% 
D lung 41.9% 
•liver 24.9% 
m brain 0.4% 
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3.2.3 Effect of mannitol on the distribution of A-LAK cells 
to the liver infused via the portal vein. 
To study the effect of intraportal mannitol on the uptake of A-LAK 
cells in the liver, a third group of 8 rats was used. In this group, prior to 
the intraportal infusion of labelled A-LAK cells, 30% mannitol was 
infused at 0.3mg/kg body weight via the portal vein cannula. Two 
hours later rats were sacrificed and the organs and blood were taken for 
radioactivity counting. The results of A-LAK cell distribution with and 
without mannitol infusion were compared, to study the effect of 
intraportal mannitol. The results of these experiments are shown in 
Table 7 and Figure 6. When intraportal mannitol was given just prior 
to A-LAK infusion, there was a significantly increased distribution of 
intraportal infused A-LAK cells into liver compared to A-LAK 
infusion without mannitol (54.05% vs 24.36%, P< 0.0005) (Table 7, 
Figure 6). To exclude the possibility that this effect of intraportal 
mannitol was a result of increased blood volume in the liver, the 
results of A-LAK cell distribution per gram of tissue were calculated, 
and are shown in Table 8 and Figure 7. The results also indicate that 
the mannitol enhanced the delivery of A-LAK cells into the liver 
(9.33%/g vs 3.89%/g P< 0.001). 
In addition, intraportal mannitol administration resulted in 
significantly increased A-LAK distribution to MLN (0.05% vs 0.02%, 
P<0.05) and to brain (0.26% vs 0.08%, P<0.05). There was no significant 
difference in A-LAK distribution to lung, spleen, kidneys or blood 
following intraportal mannitol. 
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Table 7 Comparison of %distribution of A-LAK cells per Organ 
by regional infusion with and without Mannitol 
ORGAN Without M With M P** 
%DI organ± sd * %DI organ± sd * 
blood 3.66 ±3.24 3.76 ±2.71 0.95 
spleen 0.97 ±0.80 1.0 ±1.0 0.96 
kidneys 1.78 ±2.24 1.44 ±0.81 0.69 
MLN 0.02 ±0.02 0.05 ±0.02 0.04 
lung 6.01 ±5.9 8.39 ±4.27 0.37 
liver 24.36 ±11.53 54.05 ±14.17 0.0004 
brain 0.08 ±0.11 0.26 ±0.21 0.04 
*%0 I organ= mean percentage of total dose of infused A-LAK cells, taking into account 
spontaneous isotope release, per whole organ (8 rats) 
**P- Student's t-test 
Figure 6: Graphical representation of data from Table 7 
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Table 8 Comparison of %distribution of A-LAK cells per gram 
by regional infusion with and without Mannitol 
ORGAN Without M with M P** 
%D/g± sd* %D/g± sd* 
spleen 2.23 ±1.92 2.41 ±2.58 0.87 
kidney 1.19 ±1.03 1.30 ±0.82 0.81 
MLN 1.7 ±1.9 3.20 ±1.70 0.13 
lung 6.55 ±4.31 11.2 ±5.6 0.08 
liver 3.89 ±2.52 9.33 ±2.67 0.0009 
brain 0.06 ±0.09 0.19 ±0.15 0.051 
*%DI g= mean percentage of total dose of infused A-LAK cells, taking into account 
spontaneous isotope release from cells at 2h, per gram of organ (8 rats). 
**P- Student's t-test 
Figure 7: Graphical representation of data from Table 8 
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To show that the effect of intraportal mannitol was not due to 
differences in the radioactivity in blood, Table 9 shows that there was 
no significant difference in the radioactivity in blood between the two 
groups (3.76% vs 3.66%). Table 9 also shows that the average weight of 
liver was 6.83g in group 2 and 5.89g in group 3 indicating that the 
increased radioactivity within liver in group 3 was not due to increased 
size of this organ following mannitol. 
By comparison of the total radioactivity recovered in these organs 
between two groups as shown in Table 9, it was found that the 
percentage of total recovered radioactivity was much higher in the 
mannitol group than that in the group without mannitol (69.05% vs 
35.9%, P<0.005). This is mainly because of the increased cell 
distribution to liver. 
Table 9 Comparison of % distribution of A-LAK cell in liver and 
blood by regional infusion without or with mannitol, organ weight 
and % radioactivity in whole organs. 
%distribution in 
%D* in liver ±sd weight of liver g %D* in blood ±sd detected organs 
without M 24.36 ± 11.53 6.83 ± 1.73 3.66 ±3.24 36.18 ± 15.61 
withM 54.05 ±14.17 5.89 ±0.67 3.76 ±2.71 69.05 ± 17.76 
P** 0.0004 0.1716 0.9476 0.0015 
*%D= mean percentage of total dose of A-LAK cell infused, taking into account the 
spontaneous isotope release at 2h (8 rats). 
**P- Student's t-test 
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Fig. A Morphology of rat splenocytes. Cells are obtained from the interface of Ficoll-
hypaque gradient centrifugation. It shows mixed population of microphage, 
lymphocytes and some RBC. (A) shows splenocytes under low magnifiction (x500). (B) 
shows them in a higher magnification (x1250). 
A 
Fig. B Mophology of NWP lymphocytes. These NWP (Nylon-wool unadherent) 
lymphocytes are collected from NW column after splenocytes have been incubated in 
it at 37°C for lhr. These cells are going to be cultured with lOOOU /ml IL-2 in T-75 flask. 
(A) is made under magnification of (x500). (B) is under low panel (x312). 
Fig. C The adherent LGL in culture flask. After 2-days culture of NWP lymphocytes 
with IL-2, plastic unadherent cells were washed away and adherent LGL are continuesly 
cultured. (A) shows cells are continuing expanding. (B) shows the cells are nearly fully 
expanded in flask at day-7 of culture just before cell harvest. 
A 
15 
Fig. D Morphology of A-LAK cells. A-LAK cells were harvested from culture. 
Cytospin slides are fixed in Giemsa stain. These A-LAK cells show a relatively high 
cytoplasmic: nuclear ratio with abundant cytoplasm, an eccentric reniform nucleus and 
prominent cytoplasmic granules. (A) is under lower magnification of (x500). (B) shows 
cells under magnification of (x1250). 
Chapter 4 Discussion 
-.· ... 
,•:... . -
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4.1 A-LAK Cell Generation and Characterisation 
4.1.1 A-LAK cell generation 
This study determined the distribution of A-LAK cells following 
intravenous and intraportal infusion into rats and the effect of 
intraportal mannitol on the uptake of A-LAK cells in liver. Since T 
cells have a different migration pattern to LAK cells (Rolstad et al 1986; 
Maghazachi et al 1988b, 1988c), it was essential that the LAK cells used 
in this study be as pure as possible. A-LAK cells were generated using 
the method of Vujanovic et al 1988c: LGL were isolated by stimulating 
nylon wool non-adherent splenic lymphocytes with IL-2. Following IL-
2 stimulation LGL adhere to the plastic surface of a culture flask, and 
develop into LAK cells. Following the proliferation of these LAK cells, 
a highly purified A-LAK cell population is obtained. 
Incubation of lymphocytes in a nylon wool column is designed to 
deplete B cells and macrophages from the spleen cell population. This 
study showed that B cell depletion was not as complete as several 
published studies have indicated. Schwarz et al 1989 and Vujanovic et 
al 1988c reported that use of a nylon wool column could consistently 
reduce the percentage of B cells to less than 2% and macrophages to less 
than 0.3%. In our study, the B cells among nylon wool non-adherent 
lymphocytes were much higher (12%-36%). The reason for the less 
efficient B cell depletion during nylon wool incubation is not clear. In 
another work (Wilkinson S. MD thesis) the leaching and preparation 
of the nylon wool were found to be possible factors. Fortunately there 
-
were no B cells detectable in the A-LAK cell population (Table 2), 
which suggests that the B cells. were 'unable to adhere to the plastic 
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surface in culture flask. Whether the presence of B cells in the first 2 
days culture could influence the later LAK cell prolife:i;ation has not 
been examined. 
The immunofluorescent staining study of flask nonadherent cells 
showed that cytotoxic T lymphocytes appeared in these cultures after 48 
hours (Table 1). Cytotoxic T cells were both OX19 and OXs positive. By 
removing the flask nonadherent cells, the adherent LGL/NK/LAK 
cells were separated from the activated T cells. Thus, this culture 
allowed the collection of purified A-LAK cells (purity 67-90%). 
Vujanovic et al 1988c reported that by 48h, about 4.5% of NW-non-
adherent splenocytes adhere to the culture flask plastic surface. In our 
study, the percentage of adherent cells at 48h was not determined. The 
number of culture flask adherent LGL appeared to vary from rat to rat. 
The number and concentration of the adherent LGL was an important 
factor in the later proliferation of A-LAK cells. A low number of 
adherent LGL resulted in failure of A-LAK cell proliferation. The 
factors responsible for the number of adherent LGL could be: (1). The 
percentage of LGL in the starting lymphocyte population, which 
depends on the organ and strain and possibly the age of rats (Reynolds 
et al 1981); (2). The number of nylon wool non-adherent lymphocytes 
used at the beginning of the culture. Optimal density of 2xl06 cells/ml 
was suggested by Vujanovic et al in 1988. In the present study the 
production of A-LAK cells varied markedly depending on the starting 
cell density (2xl06 /ml to 3.Sx1Q6 /ml). A greater concentration of 
starting cells usually resulted in a better culture of A-LAK cells. 
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It was observed that the A-LAK cell culture was influenced by the 
culture flask surface area to which the LGL adhered. A flask of size 
75cm2 provided a larger area for the flask adherent LGL expansion. In 
the present study, although the A-LAK cells did not achieve full 
expansion on all of the available flask surface area, the number of A-
LAK cells harvested from the large flask was proportionally more than 
that from small flasks (25cm2). 
Successful A-LAK cell culture was also influenced by the LGL response 
to IL-2. In this study, there were several instances of failure of cell 
proliferation to IL-2. Loss of IL-2 receptors could be one reason for this. 
Another possible reason (Vujanovic et al 1988c) is that both suppressor 
T cells (Ts) and monocytes may inhibit the proliferation of LAK cells in 
bulk culture. It is possible that the presence of T suppressor cells in the 
first 2 days of culture could result in a high concentration of T s 
products in the culture supernatant which inhibited LGL expansion. 
However, the use of the conditioned medium in these cultures for 
subsequent successful expansion of A-LAK cells implied that such 
factors were not present or were of short half life. 
4.1.2 A-LAK cell identification 
In this study A-LAK cells were characterised by immunofluorescent 
staining, morphological identification and cytotoxic analysis.' 
The phenotypic profile of A-LAK cells in this work is in agreement 
with previous published studies (Schwarz et al 1989; Vujanovic et al 
1988c; Maghazachi et al 1988c). The majority cells from adherent cell 
. ' 
culture were OXs positive . A-LAK .cells with only about 5% OX19 
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positive cells. Between 80%-100% of LAI< cells should be OXs positive 
and these cells should be OX19 negative. OX19 (CDS) i~ a pan T cell 
marker (Vujanovic et al 1988a; Chambers et al 1989; Ortaldo et al 
1986). Though some OXs positive cells could be T cells, T cells should 
be OX19 positive as well. Therefore the phenotypic profile of cells in 
this study is consistent with the recognized pattern for A-LAK cells. 
Though antibody 3.2.3 is the most specific antibody for A-LAK cells at 
the present time, it was not available nor used in this study. OX34 is the 
Mab which reacts with the CD2 surface marker (Reynolds et al 198lb; 
Ortaldo et al 1981; Williams et al 1987). The results in this study suggest 
that OX34 may react with both A-LAK cells and T cells. There were no 
previous studies found which tested this Mabon A-LAK cells. 
Morphological analysis of A-LAI< cells in the rat using Giemsa-stained 
cytocentrifuge preparations indicated that A-LAK cells had a 
morphology consistent with previously published studies (Melder et al 
1988; Vujanovic et al 1988c; Sasaki et al 1989). Morphological study of 
LGL was not carried out in this study. The comparison of the 
morphology of LGL with A-LAK, which would show the size of cells 
before and after stimulation by IL-2, was not carried out. Sasaki et al 
1989 has demonstrated that LAI< cells have a greater mean diameter 
than nonactivated LGL. 
Cytotoxicity assay results in this study confirm that the cells from the 
A-LAK cell culture were predominantly A-LAK cells, as A-LAK cells 
showed high ability to lyse cultured YAC-1 and P-815 cells in 4h 51Cr-
release cytotoxic assays. 
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4.2 Distribution of s1cr-labelled A-LAK Cells in the Rats 
4.2.1 51Cr-labelling of A-LAK cells 
To study the distribution of radiolabelled A-LAK cells in rats by 
systemic and regional infusion, and the effect of intraportal mannitol 
on the uptake of LAK cells into liver, A-LAK cells were radiolabelled 
with 51Cr before being infused into rats. 51Cr is a commonly used 
radioisotope for monitoring the migration pattern of lymphocytes in 
viva. This isotope has many advantages and few disadvantages 
compared with other isotopes such as 3H, 14C, 75Se, 99mTc and 125I in 
lymphocyte trafficking studies (Rannie et al 1977). 
The presence of radioactivity in the organs following cell infusion may 
be due to radiolabelled cells, free 51Cr, or spontaneously released 51Cr. 
In this study it is important to ensure that the radioactivity in the 
organs really reflects the presence of LAK cells rather than free isotope. 
To exclude the presence of free 51Cr from the infused cell supernatant 
the radio labelled cells were washed thoroughly. The washing 
eliminated 51Cr from the superna~ant of infused cells as shown in 
Table 3. The other potential source of free isotope is the spontaneous 
release of 51Cr during the two hour circulation inside the rat. This 
problem could affect the trafficking study result in two ways. Firstly, 
once the 51Cr is released from the cells the radioactivity per infused cell 
will be decreased. The radioactivity of cells detected before infusion 
would therefore no longer be a reflection of the migrating cell numbers 
in viva. Since the percentage of cell distribution in organs is calculated 
based on the total radioactivity of cells injected (formula in 2.2.3), the 
radioactivity within cells should be known as accurately as possible. 
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Secondly, if the released 51Cr accumulated in organs the radioactivity 
in the organs no longer reflects the presence of LAK cells .. To obtain the 
radioactivity in cells 2h following infusion, some cells were incubated 
for two hours and the percentage of 51Cr released into the supernatant 
was calculated (see the formula for the SR in 2.2.1). The radioactivity 
obtained in the SR was then subtracted from the radioactivity of the 
infused cells (Table 3). In this way the first source of error is excluded. 
This is based on the assumption that spontaneous release in vitro is 
approximately equivalent to the rate of SR in vivo. From this study 
there was no correlation between the spontaneous release and the % 
distribution of radioactivity in body organs (Table E of Appendix), 
which suggests that there was no significant accumulation of released 
Slcr in tissues. It has been demonstrated that the free 51Cr is efficiently 
removed through urinary excretion and not retained in tissues 
(Rannie et al 1977; LeFever et al 1987). Basse et al 1992b found that 24h 
following cell infusion, released 51Cr accumulated in the liver. The 
present study does not show correlation between spontaneous 51Cr 
release and radioactivity in the liver (Table E of Appendix), which 
indicates that at 2h the radioactivity in liver is not resultant from 
accumulation of free 51Cr. 
It has been suggested that dead cells may accumulate in the liver after 
infusion. It is possible that the dead cells still carry some radioactivity 
after 2h. LeFever et al 1987 found a linear correlation between viability 
of the cell population injected and the amount of radioactivity detected 
in the kidneys. In the present study the cell viability at infusion was 
usually greater than 90%. Maghazachi et al l988c found that the 
radioactivity obtained from the lungs, liver and spleen after injection 
of intact cells was not due to dead cells' or free s1cr. 
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4.2.2 A-LAK cell distribution 
This study shows that the distribution of A-LAK cells in the liver is 
slightly higher at 2h following regional portal vein infusion compared 
to systemic infusion, however results do not reach statistical 
significance. Bass et al 1992b has found increased accumulation of A-
LAI< cells in the liver 24h after portal infusion. However this study has 
found that prior portal infusion of mannitol further increases LAK cell 
distribution to the liver, to a significantly higher level than regional 
infusion without mannitol. 
The early distribution of A-LAI< cell in the organs differs with the 
route of administration, that is, systemic (via the tail vein) and 
regional (via portal vein). Comparing systemic to regional infusion, it 
was found that an increased number of A-LAK cells distributed to the 
liver following regional injection (as shown in Table 5). Other organs, 
particularly the lung show increased numbers of A-LAI< cells via 
systemic infusion. Results (in Table 5) indicate that portal vein 
infusion decreases the early accumulation of LAK cells in lungs ( 6.01 % 
vs 15.65% ). The effect of regional infusion is more clearly shown by 
looking at the percentage distribution of LAI< cell per gram of lung 
tissue (6.55% per gram vs 19.02% per gram, P<0.05, Table 6). However, 
irrespective of the route of infusion, a large proportion of A-LAK cells 
do accumulate in the lungs (Figure 4 and 5). This result has also been 
obtained by other investigators (Reynolds et al 1984; LeFever et al 1984; 
Maghazachi et al 1988c, 1988b; Rannie et al 1977; Felgar et al 1990). The 
results shown in Fig. 4 and Fig. 5 indicate that the retention of LAK 
cells in lungs is not solely related to the route of systemic infusion. 
. . . 
Systemic infusion of A-LAI< cells results in the early entrapment of 
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these cells in the lung capillary bed. By regional infusion, the early 
retention of A-LAI< cells in the lung is decreased. However, A-LAK 
cells are still mainly accumulated in the lungs. LAK cells tend to 
localise in lungs much more than do non-activated T lymphocytes 
(Lotze et al 1980; Reynolds et al 1984; Maghazachi et al 1988c; Marincola 
et al 1988). There are several explanations for the preferential 
accumulation of LAK cells by the lungs. Lotze et al 1980 indicated that 
cell membrane alteration may be induced by the growth of these 
cultured cells in the presence of IL-2 and may explain their altered 
migration ability. LAK cells are large and this probably explains their 
early trapping in the lung. Sasak et al 1989 and Worthen et al 1989 also 
showed that A-LAI< cells were rigid in comparison with other 
nonactivated lymphocytes. Structural rigidity is known to influence 
the behaviour of cells in the capillaries by hindering their passage 
through small capillaries and altering their haemodynamic behaviour 
in postcapillary venules. Maghazachi et al 1988b indicated that LAK 
cells may have carbohydrate-binding protein which allows them to 
bind to endothelial cells lining the lung vessels. Thus, the reasons for 
the early high retention of A-LAK cells in the lung appear largely 
related to the morphology of A-LAK cells, the high rigidity of these 
cells and the nature of the LAK cell surface membrane. 
Clinical trials have shown that one side effect of high dose 
administration of IL-2 and LAK cell therapy is a capillary leak 
syndrome including pulmonary oedema (Rosenberg et al 1987). Damle 
et al 1987 and Aronsonet al 1988 showed that LAK cells can lyse 
cultured endothelial cells in vitro. Thus LAK cells may damage 
endothelial cells in the lungs, which may contribute to pulmonary 
oedema. Infused LAK cells recovered from the lungs are still viable 
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and cytolytic (LeFever et al 1987). Since the regional infusion of LAK 
cells decreases the early retention of these cells in the lung capillary 
bed, it is possible that this side effect may be reduced by this route of 
infusion. Further study is required to determine whether regional 
infusion merely delays the accumulation of these cells in lungs. 
The present study also found that A-LAK cells distributed to MLN 
following eith~r systemic or regional infusion. The results {Table 6) 
show that 1.7% of infused radioactivity is recovered per gram of MLN, 
which is comparable to that in liver (2.15% per gram) and spleen 
(2.77% per gram). This result is consistent with findings obtained by 
other investigators which have indicated that LAK cells have the 
ability to localise in LN (Ettinghausen et al 1985; Marincola et al 1988; 
Harcel et al 1991). It has been demonstrated that activated T 
lymphocytes lose the ability to localise to LN (LeFever et al 1984). This 
change has been considered to be attributed to the loss of HEV receptors 
and other differences in cell surface carbohydrate composition (Dailey 
et al 1982; Carroll et al 1983). 
The main purpose of present study was to investigate the effect of 
intraportal mannitol on the distribution of LAK cells to liver. The 
comparison of the uptake of LAK cells in liver following portal vein 
administration with and without mannitol showed that intraportal 
mannitol can significantly increase the uptake of A-LAK cells in liver 
{Table 7). The mechanif:?m of increased distribution of A-LAK cells to 
liver following mannitol infusion is most likely due to the effect of 
mannitol on the endothelial vascular cells. Previous studies have 
demonstrated that mannitol has the effect of opening the Blood-Brain 
Barrier. The mechanism by whi~h mannitol achieves this effect is by 
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increasing the intercellular gap between capillary endothelial cells 
(Franceschini et al 1988). Mannitol as a hyperosmolar. solution has 
been shown to enhance the distribution of chemical agents into brain. 
The increased space between endothelial cells enables the large and 
rigid LAK cells to pass through the capillary wall into tissue. The effect 
of intraportal mannitol is further evidence that the limited pattern of 
LAK cell distribution in vivo is probably due to their large size and 
rigidity. 
Immunohistochemical analysis was not carried out to obtain primary 
evidence of the histological localisation of adoptively transferred LAK 
cells. However the isotope trafficking study does suggest that these cells 
have been delivered into tissue {Table 8 and 9). 
Mannitol has the effect of reducing the extravascular fluid in organs, 
therefore decreasing the interstitial pressure in tissues. The normal 
difference between vascular pressure and interstitial pressure may be 
responsible for inhibiting transvascular movement of LAK cells, ie. 
when interstitial pressure is higher than intravascular pressure, LAK 
cells have greater difficulty in passing into tissue because they have to 
move against a pressure- gradient. After interstitial pressure is 
decreased by mannitol, LAK cells may pass through more easily. 
The results show that there is only a very limited distribution of LAK 
cells to the brain even after the administration of mannitol {Table 7 
and Table 8). The influence of interstitial pressure on the LAK cell 
migration is not a satisfactory explanation for poor distribution of LAK. 
cells to brain. Although mannitol can decrease the interstitial pressure, 
the characteristics of this organ 111-ay have a more important role which 
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limits the distribution of LAK cells to this organ. Rannie et al 1977 has 
found that the central nervous tissue consistently gave the lowest 
concentration of radioactivity when the distribution of lymphocytes 
was studied. 
Once LAK cells have accumulated in tissue it is possible that the 
closing of the capillary inte~cellular spaces may prevent the escape of 
entrapped A-LAK cells. Mannitol is only able to open the intercellular 
spaces for a limited time. Thus it is possible that once mannitol ceases 
to have any effect, the endothelial cells are able to revert to normal and 
prevent escape of A-LAK cells. 
The optimal time between infusion of mannitol and delivery of LAK 
cells is uncertain. LAK cells infused too late after the infusion of 
mannitol would be unable to utilise the physiological effects of 
mannitol efficiently. The continuous infusion of mannitol is not 
recommended until the effect of prolonged mannitol administration 
on the uptake of LAK cells has been studied. The escape of LAK cells 
may occur when the entrapment of cells in the tissue reaches a certain 
level. Futher study will be required to confirm this. 
The effect of mannitol on the delivery of LAK cells to tumour sites and 
liver metastases is of major interest. The microvasculature in tumour 
and metastases have different characteristics from normal tissues. In 
tumours the vessels are dilated, saccular, and tortuous Gain 1988), and 
the blood flow is slow and even absent in the centre of the tumour. 
The interstitial pressure is higher towards the centre of tumour and 
the intercapillary distance is increased with tumour growth Gain 1989). 
It has been demonstrated that :LAK ·cells take significantly longer to 
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bind to tumour vasculature compared to normal vasculature, probably 
because of abnormal microvascular surface characteristics of tumours 
(Sasaki et al 1991). These characteristics may limit the direct effects of 
mannitol on tumour circulation and LAK cells may have difficulty in 
reaching all tumour sites. Thus in a small tumour lesion th~ 
entrapment of cells may be more efficient than in a large one due to 
the increased high interstitial pressure area in the larger tumour. 
The present study shows that the distribution of LAK cells in normal 
tissue is increased by mannitol. It is possible that mannitol could 
improve the accumulation of LAK cells within tumour. Little is 
known about whether tumour micro-circulation characteristics would 
limit the distribution of LAK cells. Further investigations is necessary 
to examine the effect of intraportal mannitol on LAK cell uptake over 
a longer time period, (for example twenty four hours) in normal 
tissues as well within tumour in liver. In addition it will be important 
to determine if these protocols result in longer survival for tumour-
bearing rats. 
In summary, this study provides evidence that intraportal infusion of 
mannitol may increase the distribution of intraportally infused A-LAK 
cells to the liver during adoptive immunotherapy. Regional infusion 
of LAK cells may have the additional effect of limiting the 
accumulation of A-LAK cells in the lung with a possible reduction in 
pulmonary oedema. 
82 
Bibliography 
Aarden,L.A., Brunner,T.K., Cerottini,J.C., Dager,J.M., de Weck,A.L., Dinarello, C.A., 
Di Sabato, G., Farrar,I.J., Gery,I., Gillis,S., Handschumacher,R.E., Henney, C.S., 
Hoffmann,M.K., Koopman,W.J., Krane,S.M., Lachman,L.B., Lefkowits, L., 
Mishell,R.I., Mizel,S.B., Oppenheim,I.J., Paetkau,V., Plate,J., Rollinghoff,M., 
Rosenstreich,D., Rosenthal,A.S., Rosenwasser,L.J., Schimpl,A., Shin,H.S., 
Simon,P.L., Smith,K.A., Watson,J.D., Wecker,E., Wood,D.D, Letter to the Editor, 
Revised Nomenclature for antigen-nonspecific T-cell proliferation and helper 
factors. J.Immunol. 1979 123, 2928-2929 
Abrams,J.S., Eiseman,J.L., Melink,T.J., Sridhara,R., Hiponia,D.J., Bell,M.M., 
Belani,C.P., Adler,W.H., Aisner,J., Immunomodulation of interleukin-2 by 
cyclophosphamide: a phase !B trial. (abstract) J. Immunother. 1993 14(1) 56-64 
Akporiaye,E.T., Kudalore,M., Stevenson, A.P., et al. Isolation and reactivity of host 
effectors associated with the manifestation of concomitant tumor immunity. Cancer 
Res. 1988 48, 1153-1158 
Ames,I.H., Gagne,G.M., Garcia,A.M., John,P.A., Scatorchia,G.M., Tomar,R.H., and 
McAfee,J.G., Preferential homing of tumor-infiltrating lymphocytes in tumor-
bearing mice Cancer Immunol. Immunother. 1989 29, 93-100 
Andriole,G.L., Mule,J.J., Hansen,C.T., Linehan,W.M., and Rosenberg,S.A., 
Communication. Evidence that lymphokine-activated killer cells and natural 
killer cells are distinct based on an analysis of congenitally immunodeficient mice. 
J.Immunol. 1985 135 2911-2913 
Aronson,F.R., Libby,P., Brandon,E.P., Janicka,M.W., Interlrukin-2 rapidly induces 
Natural Killer cell adhesion to human endothelial cells. J.Immunol. 1988 141, 
158-173 
Atkins,M.B., Gould,J.A., Allegretta,M., Li,J.J., Dempsey,R.A., Rudders,R.A., 
Parkinson,D.R., Reichlin,S., and Mier,J. Phasel evaluation of recombinant 
interleukin-2 in patient with advanced malignant disease. J.Clin.Oncol., 1986 4, 
1380-1391 
Ballas,Z.K., Lymphokine-activated killer cells. I. Differential recovery of LAK, 
natural killer cells and cytotoxic T lymphocytes after a sublethal dose of 
cyclophosphamide. J.Immunol. 1986 137, 2380-2384 
Ballas,Z.K., Rasmussen,W., and Otegham,J.K.V., Lymphokine-activated killer 
(LAK) cells II. Delineation of distinct murine LAK-precursor subpopulation. J. 
Immunol. 1987 138, 1647-1652 
Basse,P.H., Nannmark,U., - Johansson,B.R., Herberman,R.B., Goldfarb,R.H., 
Establishment of cell-to-cell contact by adoptively transferred adherent 
lymphokine-activated killer cells with metastatic murine melanoma cells. J. 
Natl. Cancer Inst. 1991a 83, 944-950 
Basse,P.H, Herberman,R.B., Nannmark,U., Johansson,B.R., Hokland,M., 
Wasserman,K., and Goldfarb,R.H., Accumulation of adoptively transferred 
adherent lymphokine-activated killer cells in murine metastases. J.Exp.Med. 
1991b 174, 479-488 
Basse,P.H., Herberman,R.B., Hokland,M., and Goldfarb,R.H., Tissue distribution of 
adoptively transferred adherent lymphokine-activated killer cells assessed by 
different cell labels. Cancer Immunol. Immunther. 1992a 34, 221-227 
Basse,P.H., Herberman,R.B., Hokland,M., and Goldfarb,R.H., Tissue distribution of 
adoptively transferred adherent lymphokine-activated killer cells: role of the 
route of administration. Nat. Immun. 1992b 11, 193-202 
Belli,F., Arienti,F., Rivoltini,L., Santinami,M., Mascheroni,L., Prada,A., 
Ammatuna,M., Marchesi,E., Parmiani,G., Cascinelli,N., et al Treatment of 
recurrent in transit metastases from cutaneous melanoma by isolation perfusion in 
extracorporeal circulation with interleukin-2 and lymphokine activated killer 
cells. A pilot study. (abstract) Melanoma R~s. 1992 2(4) 263-271 
83 
Benyunes,M.C., Massumoto,C., York,A., Higuchi,C.M., Buckner,C.D., Thompson,J.A., 
Petersen,F.B., Fefer,A., Interleukin-2 with or without lymphokine-activated 
killer cellers as consolidative immunotherapy after autologous bone marrow 
transplantation for acute myelogenous leukemia. (abstract) Bone Marrow 
Transplant 1993 12(2) 159-163 
Berenson,J.R., Einstein, A.B., and Fefer,A., Syngeneic adoptive immunotherapy and 
chemoimmunotherapy of a friend leukemia: requirment for T-cells, J. Immunol., 
1975 115, 234-238 
Bjerknes,M., Cheng,H., and Ottaway,C.A., Dynamics of lymphocyte-endothelial 
interaction in vivo. Science 1986 28, 402-405 
Brink,Marcel R.M. van den, Boggs,S.S., Herberman,R.B., Hiserodt,J.C., The 
generation of nayural killer(NK) cells from NK precursor cells in rat long-term bone 
marrow cultures. J.Exp.Med. 1990 172, 303-313 
Burns,G.F., Triglia.T., and Werkmeister,J.A., In vitro generation of numan activated 
lymphocyte killer cells: separate precursors and modes of generation of NK-like 
cells and "anomalous" killer cells. J. Immunol. 1984 133, 1656-1663 
Caligiuri,M.A., Murray,C., Soiffer,R.J., Klumpp,T.R., Seiden,M., Cochran,K., 
Cameron,C., Ish,C., Buchanan,L., Perillo,D., et al. Extended continuous infusion 
low-dose recombinant interleukin-2 in advanced cancer: prolonged 
immunomodulation without significant toxicity. (abstract) J. Clin.Oncol. 1991 9, 
2110-2119 
Cantrell,D.A., Robins,R.A., Brooks,C.G., and Baldwin,R.W., Phenotype of rat natural 
killer cells defined by monoclonal antibodies marking rat lymphocyte subsets. 
Immunology 1982 45, 97-103 
Carroll,A.M., Palladino,M.A., Oettgen,H., DeSousa,M., In vivo localization of 
cloned IL-2 dependent T cells. Cell Immunol. 1983 76, 69-80 
Chambers,W.H., Vujanovic,N.L., DeLeo, A.B., Olszowy,M.W., Herberman,R.B., and 
Hiserodt,J.C., Monoclonal antibody to a triggering structure expressed an rat 
natural killer cells and adherent lymphokine-activated killer cells. J.Exp.Med. 
1989 169, 1373-13899 
Cheever,M.A., Greenberg,P.D., Fefer,A., Specific adoptive therapy of established 
leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro 
and non-specifically expanded by culture with Interleukin 2, J. Immunol. 1981 126, 
1318-1322 
Chen,D.H., Ultrastructure study of the lethal effect of lymphokine activated killer 
(LAK) cell on liver cancer cells. (abstract) 1991 
Chong,AS-F., Scuderi,P., Grimes, W.J., et al. Tumor targets stimulate IL-2 activated 
killer cells to produce interferon and tumor necrosis factor. J.Immunol. 1989 142, 
2133-2139 
Colombo,M.P., Parenza,M., and Parmiani,G., Adoptive immunotherapy of a BALB/c 
lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of 
the effector population and evidence for the role of the host's non-T cells. Cancer 
Immunol. Immunother 1985 20, 198-204 
Damle,N.K., Doyle,L.V., Bender,J.R., and Bradley,E.C., Interleukin-2-activated 
human lymphocytes exhibit enhanced adhesion to normal vascular endothelial 
cells and cause their lysis. J.Immunol. 1987 138, 1779-1785 
Da Pozzo,L.F., Hough,K.L., Holder,W.D.Jr., Toxicity and immunologic effects of 
continuous infusion of recombinant human interleukine-2 administered by selective 
hepatic perfusion in dog. (abstract) Surgery 1992 111, 326-334 
Dailey,M.O., Fathman,C.G., Butcher,E.C., Pillemer,E., Weisman,!., Abnormal 
migration of T lymphocyte clones. J.Immunol. 1982 128, 2134-2136 
Donohue,J.H., and Rosenberg,S.A., In vivo administration of purified Jurkat-derived 
interleukin-2 in mice. Cancer Res., 1984 44, 1380-1386 
Engelstein,D., Shmueli,J., Kessler,O., Mukamel,E., Nussbaum,B., Hadar,H., Ossimi, 
Z., Novogrodsky,A., Servadio,C., Immunotherapy for metastatic renal cell 
carcinoma: treatment with. PLAK cells and low-dose interleukin-2. (abstract) 1992 
84 
Ettinghausen,S.E., Lipford,E.H., Mule,J.J. and Rosenberg,S.A., Systemic 
administration of recombinant interleukin-2 stimulates in viva lymphoid cell 
proliferation in tissues. J.Imm.unol. 1985a 135, 1488-1497 
Ettinghausen,S.E., Lipford,E.H. III, Mule,J.J., and Rosenberg,S. A., Recombinant 
interleukin-2 stimulates in viva proliferation of adoptively transferred 
lymphokine-activated killer(LAK) cells, J. Immunol., 1985b 135, 3624-3635 
Ettinghausen,S.E., and Rosenberg,S. A., Immunotherapy of murine sarcomas using 
lymphokine activated killer cells: optimization of the schedule and route of 
administration of recombinant interleukin-2. Cancer Res. 1986 46, 2784-2792 
Felgar,R.E., and Hiserodt,J.C., In viva migration and tissue localization of highly 
purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. 
Celluar lmmunol. 1990 129, 288-298 
Foon,K.A., Walther,P.J., Russell,D., et al. Renal cell carcinoma treated with 
continuous-infusion interleukin-2 with exvivo-activated killer cells. (abstract) J. 
lmmunother. 1992 11, 184-190 
Franceschini,V., Ciani,F., Lazzari,M., Grande,P.D., and Minelli,G., Opening of blood-
brain barrier in triturus cristatus camifex by hyperosmolar mannitol solutions. Bas. 
Appl. Histochem. 1988 32, 327-332 
Futami,H., Pilaro,A.M., Gruys,M.E., Back,T.C., Young,H.A., Wiltrout,R.H., In viva 
distribution and cytokine gene expression by enriched mouse LAK effector cells. 
(abstract) Biotherapy 1991 3, 219-232 
Gazit,Z., Weiss,D.W., Shouval,D., Yechezkeli,M., Schirrmacher,V., Notter,M., 
Walter,J., Kedar,E., Chemo-adoptive immunotherapy of nude mice implanted 
with human colorectal carcinoma and melanoma cell line. (abstract) Cancer 
Immunol. lmmunother. 1992 35,135-144 
Gillis, S. and Smith, K.A., Long term culture of tumour specific cytotoxic T-cells. 
Nature, 1977 268, ·154-156 
Gillis, S., Ferm, M.M., On, W. and Smith, K.A., T-cell growth factor: Parameters of 
production and quantitative microassay for activity. J. lmmunol 1978 120, 2027-
2032 
Gilman,S.C., Rosenberg,J.S., and Feldman,J.D., Membrane phenotype of the rat 
cytotoxic T lymphocyte. J.Immunol. 1982 129, 1012-1016 
Glasby,M.A., Mannitol penetration of liver cells in estimations of extracellular fluid 
volume, Quarterly J. Exp. Physiol. 1985 70, 585-589 
Gray,J.D., Shau,H., and Golub,S.H., Functional studies en the precursors of human 
lymphokine-activated killer cells. Cellular Immunology. 1985 96, 338-350 
Griffith,K.D., Read,E.J., Carrasquillo,J.A., Carter,C.S., Yang,J.C., Fisher,B., 
Aebersold,P., Packard,B.S., Yu,M.Y., and Rosenberg, S.A., In viva distribution of 
adoptively transferred indium-111-labeled tumour infiltrating lymphocytes and 
peripheral blood lymphocytes in patients with metastatic melanoma. J. Natl. 
Cancer Inst. 1989 81, 1709-1717 
Grimm,E.A., Mazumder,A., Zhang,H.Z., and Rosenberg,S.A., The lymphokine 
activated killer cells phenomenon: lysis of NK resistant fresh solid tumor cells by 
IL-2 activated autolous human peripheral blood lymphocytes, J.Exp.Med. 1982 
155, 1823-1841 
Grimm,E.A., Ramsey,K.M., Mazumder,A., Wilson,D.J., Djeu,J.Y., and Rosenberg,S.A., 
Lymphokine-activated killer cell phenomenon II. Precursor phenotype is 
serologically distinct from peripheral T lymphocytes, Memory cytotoxic thymus-
derived lymphocytes, and Natural Killer Cells. J.Exp.Med. 1983a 157, 884-897 
Grimm,E.A., Robb,R.J., Roth,J.A., Neckers,L.M., Lachman,L.B., Wilson,D.J., and 
rosenberg,S.A., Lymphokine-activated killer cell phenomenon. III. Evidence that 
IL-2 is sufficient for direct activation of peripheral blood lymphocytes into 
lymphokine-activated killer cells. J.Exp.Med. 1983b 158, 1356-1361 
Groothuis,D.R., Warkne,P.C., Molnar,P., Lapin,G.D., and Mikhael,M.A., Effect of 
hyperosmotic blood-brain barrier disruption on transcapillary trasport in canine 
brain tumour. J. Neurosurg. 1990 72, 441-449 
85 
Hackett,J.,JR., Bennett,M., and Kumar,V., Origin and differentiation of natural killer 
cells I. Characteristics of a transplantable NK cell precursor. J.Immunol. 1985 134, 
3731-3738 
Hackett,J., JR., Tutt,M., Lipscomb,M., Bennett,M., Koo,G., and Kumar,V., Origin and 
differentiation of natural killer cells II. Functional and Morphologic studies of 
purified NK-1.1+ cells. J.Immunol. 1986 136, 3124-3131 
Han,F.G., Treatment of advanced liver cancer by autologous and/or homologous LAK 
cells combined with human natural IL-2. (Abstract) 1991 
Hank,J.A., Kohler,P.C., Hillman,G.W., Rosenthal,N., Moore,K.H., Storer,B., 
Minkoff,D., Bradshaw,J., Bechhofer,R., and Sondel,P.M., In vivo induction of the 
Lymphokine-activated Killer Phenomenon: Interleukin-2(IL-2) dependent Human 
Non-Major Histocompatibility Complex-restricted Cytotoxicity generated in vivo 
during administration of hllil\an recombinant IL-2, Cancer Res., 1988 48, 1965-1971 
Harcel,R.M., Brink,V., Palomba,M.L., Basse,P.H., and Hiserodt,J.C., In situ 
localization of 3.2.3.+ natural killer cells in tissues from normal and tumour-
bearing rats. Cancer Res. 1991 51, 4931-4936 
Harker,W.G., Tom,C., McGregor,J.R., Slade,L., and Samlowski,W.E., Human tumor 
cell line resistance to chemotherapeutic agents does not predict resistance to 
natural killer or lymphokine-activated killer cell-mediated cytolysis, Cancer 
Res. 1990 SO, 5931-5936 
Hayakawa,M., Koyama,Y., Williams,R.D., Osawa,A., Lymphokine-activated 
killer traffic assay and our preliliminary clinical results of regional arterial 
infusion of lymphokine-activated killer cells for renal cell carcinoma. (abstract) 
1991 
Hayakawa M., Lymphokine-activated Killer (LAK) therapy for advanced renal 
cell carcinoma: clinical study on arterial LAK therapy and experimental study en 
LAK cell activity. (Abstract) 1992 
Herberman,R.B., et al., lymphokine-activated killer cell activity. Characteristics of 
effector cells and their progenitors in blood and spleen. Immunology Today 1987 
8, 178-181 
Hercend,T., Griffin,J.D., Bensussan,A. et al., Generation of monoclonal antibodies to a 
human natural killer clone. Characterization of two Natural Killer-associated 
antigens, NKHlA and NKH2, expressed on subsets of Large Granular Lymphocytes. 
J.Clin.Invest. 1985 75, 932-943 
Hersey,P. and Bolhuis, R., Nonspecific MHC-unrestricted killer cells and their 
receptors. Immunol. Today, 1987 8, 233-239 
Hiesiger,E.M., Voorhies,R.M., Basler,G.A., Lipschutz,L.E., Posner,J.B., and 
Shapiro,W.R., Opening the Blood-Brain and Blood-Tumour Barriers in 
experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol en 
capillary permeability and blood flow. Annals Neurol. 1986 19, 50-59 
Houthoff,H.A., Go, K.G.,and Gerrits,P.O., The mechanism of blood-brain barrier 
impairment by hyperosmolar perfusion, Acta Neuropathol. 1982 56, 99-112 
lbayashi,Y., Yamaki,T., Kawahara,T., Daibo,M., Kubota,T., Uede,T., Tanabe,S., 
Hashi,K., Effect of local administration of lymphokine-activated killer cells and 
interleukin-2 on maliganant brain tumour patients. Neurol. Med. Chir. (Abstract) 
1993 33(7), 448-457 
Itoh,K., Suyaki,R., Umeyu,Y., Hanaumi,K., and Kumagai,K., Studies on murine large 
granular lymphocytes. II. Tissue, strain age and distribution of LGL and LAL. 
J.Immunol. 1982 129, 395-400 
Itoh,K., Tilden,A.B., Kumagai,K., and Balch,C.M., Leu-11+ Lymphocytes with 
natural killer(NK) activity are precursors of recombinant interleukin 2. (rIL-2)-
induced activated killer(AK) cells. J.Immunol. 198Sa 134, 802-807 
Itoh,K., Tilden,A.B., and Balch,C.M., Role of interleukine 2 and a serum suppressive 
factor an the induction of activated killer cells cytotoxic for autologous human 
melanoma cells. Cancer Res. 198Sb 45, 3173-3178 
ltoh,K., Tilden,A.B., and Balch,C.M., Lysis of human solid tumour cells by 
lymphokine-activated natural killer cells. J.Immunol. 1986 136, 3910-3915 
86 
Jain,R.K., Determinants of tumour blood flow: a review. Cancer Res. 1988 48, 2641-
2658 
Jain,R.K., Commentary. Delivery of novel therapeutic agents in tum.or: physiological 
barriers and atrategies J. Natl. Cancer Inst. 1989 81, 570-576 
Keilholz,U., Schlag,P., Tilgen W., Brado B., Galm,F., Gorich,J., Kauffman,G.W., 
Moller,P., Schneider,S., Hunstein W., Regional administration of lymphokine-
activated killer cells can be superior to intravenous application. Cancer 1992 69, 
2172-2175 
Koenig,H., Goldstone,A.D., and Lu,C.Y., Polyamines mediate the reversible opening 
of the blood-brain barrier by the intracarotid infusion of hyperosmolal mannitol. 
Brain Res. 1989 483, 110-116 
Kotasek,D., Vercellotti,G.M., Ochoa,A.C., et al, Mechanism of cultured endothelial 
cell injury induced by lymphokine-activated killer cells. Cancer Res. 1988 48, 
5528- 5532 
Kuebler,J.P., Whitehead,R.P., Ward,D.L., Hemstreet,G.P., Bradley,E.C., Treatment 
of metastatic renal cell carcinoma with recombinant interleukin-2 in combinateion 
with vinblastine or lymphokine-activated killer cells. (abstract) J. Urol. 1993 
150(3) 814-820 
Kumagai,K., Itoh,K., Suzuki,R., Hinuman,S., and Saitoh.F., Studies of murine large 
granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities. 
J. Immunol. 1982 129, 388-394 
Kuppen,P.J., Marinelli,A., Camps, J.A., Pauwels E,K., van de Velde CJ, Fleuren, G.J., 
and Eggermont A.M., Biodistribution of lymphokine-activated Killer (LAK) 
cells in Wag rats after hepatic-artery or jugular-vein infusion. (abstract) Int. J. 
Cancer 1992 52, 266-270 
Lafreniere,R., and Rosenberg,S.A., Successful immunotherapy of murine experimental 
hepatic metastases with lymphokine-activated killer cells and recombinant 
interleukin-2, Cancer Res. 1985a 45, 3735-3741 
Lafreniere,R., and Rosenberg,S.A., Adoptive immunotherapy of murine hepatic 
metastases with lymphokine activated killer(LAK) cells and recombinant 
interleukin-2(RIL-2)can mediate the regression of boyh immunogenic and 
nonimmunogenic sarcomas and an adenocarcinoma, J.Immunol., 1985b 135, 4273-
4280 
Lafreniere,R., Rosenstein,M.S., and Rosenberg,S.A., Optimal methods for generating 
expanded lymphokine activated killer cells capable of reducing established 
murine tumours in vivo J. Immunol. Methods. 1986 94, 37-49 
Lanier,L.L., Le,A.M., Phillips,J.H., et al., Subpopulation of Human Natural Killer 
cells defined by expression of the Leu-7(HNK-1) and Leu-ll(NK-15) antigens. 
J.Immunol. 1983 131, 1789-1795 
LeFever,A.V., Truitt,R.L., Shih,C.C-Y., Liepins,S.A., and Bortin,M.M., Migration 
patterns and functional activity of cloned cytotoxic T lymphocytes in syngeneic and 
allogeneic mice. Transplantation 1984 37, 410-417 
LeFever,A.V., and Truitt,R.L., Migration of cytotoxic effector cells. Cellular 
Immunother. Cancer 1987 313-324 
Leonard, W.J., Depper,J.M., Uchiyama,T., Smith,K.A., Waldmann,T.A., Green,W. 
C., A monoclonal antibody that appears to recognize the receptor for human T-cirll 
growth factor; partial characterization of the receptor. Nature, 1982 300, 267-
269 
Lotze,M.T., Line,13.R., Mathisen,D.J., and Rosenberg,S.A., The in vivo distribution of 
autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): 
implications for the adoptive immunotherapy of tum.ors. J.Immunol. 1980 125, 
1487-1493 
Lotze,M.T., Grimm,E.A., Mazumder,A., Strausser,J.L., and Rosenberg,S.A., Lysis of 
fresh and cultured autologous tumor by human lymphocytes cultured in T -cell 
growth factor. Cancer Res. 1981 41, 4420-4425 
Lotze,M.T., Matory,Y.L., Etting~ausen,S.E:, Rayner,A.A., Sharrow,S.O., Seipp, 
C.A.Y., Custer,M.C., and Rosenberg,S.A., In vivo administration of purified human 
87 
interleukin-2. II. Half life, immunologic effects, and expansion of peripheral 
lymphoid cells in vivo with recombinant IL-2, J.Immonol. 1985 135, 2865-2875 
Lotzova,E., Savary,C.A., and Herberman,R.B., Induction of NK cell activity against 
fresh human leukemia in culture with interleukin-2. J.Immunol. 1987 138, 2718-
2727 
Maghazachi,A.A., Vujanovic,N.L., Herberman,R.B., and Hiserodt,J.C., Lymphokine-
activated killer cells in rats. Iv. Developmental relationships among Large 
Agranular lymphocytes, Large Granular Lymphocytes, and Lymphokine-activated 
killer cells. J. Immunol. 1988a 140, 2846-2852 
Maghazachi,A.A., Goldfarb, R.H., and Herberman,R.B., Influence of T cells on the 
expression of lymphokine-activated killer cell activity and in vivo tissue 
distribution. J.Immunol. 1988b 141, 4039-4046 
Maghazachi, A.A., Herberman,R.B., Vujanovic, N.L., and Hiserodt, J.C., In vivo 
distribution and tissue localization of highly purified rat lymphokine-activated 
killer(LAK) cells. Cellular Immunol. 1988c 115, 179-194 
Maghazachi,A.A., Goldfarb,R.H., and Herberman,R.B., Effect of carbohydrates m 
the in vivo migration of purified LAK cells. In Natural Killer Cells and Host 
Defense. E.W. Ades. and C.Lopez, eds. Karger Basel, pp 242 1989. 
Maghazachi,A.A., and Fitzgibbon,L., Fate of intravenously administered rat 
lymphokine-activated killer cells labeled with different markers. Cancer 
Immunol. Immunother. 1990 31, 139-145 
Marincola,F.M., Drucker,B.J., Keeling,C.A., Siao,D.Y., Starnes,H.F.,· Goodwin,D.A., 
Holder,W.D., Jr., The in vivo distribution of human peripheral blood lymphocytes 
and lymphokine-activated killer cells adoptively transferred in human pancreatic 
cancer-bearing nude mice. Surgery 1988 105, 79-85 
Marincola,F.M., DaPozzo,L.F., Howick,J.C., Drucker,B.J., Hough,K.L., and 
Holder,W.D., Prolonged survival of nude mice bearing human pancreatic cancer 
and treated with lymphokine-activated killer cells and Interluekin-2, Current 
Surgery 1989 7, 304-307 
Mazumder,A., and Rosenberg, S.A., Successful immunotherapy of natural killer-
resistant established pulmonary melanoma metastases by the intravenous 
adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2, 
J.Exp.Med. 1984 159, 495-507 
McClay,E.F., and Slovin,S.F., Immunotherapeutic approaches to the treatment of 
bone and soft tissue sarcomas, Seminars Oncol. 1989 16, 328-332 
McCoy,J.P., Yanez,K.H., Brumfield,A., Herberman,R.B., and Chambers,W.H., 
Cellular Immunol. 1990 127, 275-283 
McCutcheon,I.E., Baranco,R.A., Katz,D.A., and Saris,S.C., Adoptive immunotherapy 
of intracerebral metastases in mice, J.Neurosurg 1990 72, 102-109 
Melder,R.J., Whiteside, T.L., Vujanovic,N.L., Hiserodt, J.C., and Herberman,R.B., A 
new approach to generating antitumor effectors for adoptive immunotherapy using 
human adherent lymphokine-activated killer cells. Cancer Res. 1988 48, 3461-
3469 
Merluzzi, V.J., Comparison of Murine lymphokine- activated killer cells, natural 
killer cells, and cytotoxic T lymphocytes. Cellular Immunol. 1985 95, 95-104 
Merluzzi,V.J., Smith,M.D., and Last-Barney,K., Short communications. Similarities 
and distinctions between murine natural killer cells and lymphokine-activated 
killer cells . Cellular Immunol. 1986 100, 563-569 
Midis, G.P., Fabian, D.F., Lefor,A.T., Lymphocyte migration to tumours after 
hyperthermia and immunotherapy. (abstract) J. Surg. Res. 1992 52, 530-536 
Migliori, R.J., Gruber,S.A., Sawyer,M.D., Hoffman,R., Ochoa,A., Bach,F.H., and 
Simmons,R.L., Lymphokine-activated killer (LAK) cells can be focused at sites of 
tumor growth by products of macrophage activation. Surgery 1987 102,155-162 
Miya,K., Saji,S., Furuta,T., Azuma,S., Umemoto,T., Takao,H., Katou,M., Kanno, A., 
Kaneda,N., Yamawaki,Y., Significance of antitumour effects and immunological 
response on endogenously induced LAK therapy for primary or metastatic liver 
tumour. (abstract) 1992 · · 
88 
Monod, L., Sawamura,Y., De Tribolet, N., Immunotherapy of tumour of the central 
nervous system. (abstract) 1992 
Morgan, D.A., Ruscetti, F.W., and Gallo, R., Selective in vitro growth ·of T-
lymphocytes from normal human bone marrow. Science 1976 193, 1007-1008 
Morita,T., Yonese,Y., Minato,N., In vivo distribution of recombinant interleukin-2 
activated autologous lymphocytes administered by intraarterial infusion in 
patients with renal cell carcinoma. }NCI 1987 78, 441-450 
Mule,J.J., Shu,S., Schwarz,SL., and Rosenberg,S.A., Adoptive immunotherapy of 
established pulmonary metastases with LAK cells and recombinant interleukin-2, 
Science, 1984 225, 1487-1489 
Mule,J.J., Shu,S., and Rosenberg, S.A., The antitumor efficacy of lymphokine-
activated killer cells and recombinant interleukin-2 in vivo. J. Immunol. 1985 135, 
646-652 
Mule,J.J., Yang,J., Shu,S., and Rosenberg,S.A., The antitumor efficacy of lymphokine-
activated killer cells and recombinant interleukin-2 in vivo: direct correlation 
between reduction of established metastases and cytolytic activity of lymphokine-
activated killer cells, J. Immunol., 1986a 136, 3899-3909 
Mule,J.J., Ettinghausen,S.E., Spiess,P.J., Shu,S., and Rosenberg,S.A., Antitumor 
efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in 
vivo: Survival benefit and mechanisms of tumor escape in mice undergoing 
immunotherapy, Cancer Res. 1986b 46, 676-683 
Nakano,E., Iwasaki,A., Seguchi,T., Sugao H., Tada,Y., Matsuda,M., Sonoda,T., 
Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma 
with autologous lymphokine-activated killer cells and interleukin 2. (abstract) 
1991 
Nelson,H., Ramsey,P.S., Kerr,L.A., McKean,D.J., and Donohue,J.H., Regional and 
systemic distribution of anti-tumor + anti-CD3 heteroaggregate antibodies and 
cultured human peripheral blood lymphocytes in a human colon cancer xenograft. 
J.Immunol. 1990 145, 3507-3515 
Nishimura,T., Uchiyama,Y., Yagi,H., and Hashimoto,Y., Administration of slowly 
released recombinant interleukin, J. Exp. Med. 1987 165, 14-28 
Okuno,K., Onishi,H., Nakajima,!., et al. Splenic or hepatic arterial injections of 
interleukin-2 with chemotherapeutic agents for hepatic metastases. (abstract) 
1991 
Ortaldo,J.R., Sharrow,S.O., Timonen,T., and Herberman,R.B., Determination of 
surface antigen en highly purified human NK cells by flow cytometry using 
monoclonal antibodies. J.Immunol. 1981 127, 2401-2409 
Ortaldo,J.R., Mason,A., and Overton,R., Lymphokine-activated killer cells. Analysis 
of progenitors and effectors. J.Exp.Med. 1986 164, 1193-1205 
Papa,M.Z., Mule,J.J., and Rosenberg,S.A., Antitumor efficacy of lymphokine-
activated killer cells and recombinant interleukin 2 in vivo: successful 
immunotherapy of established pulmonary metastases from weakly immuunogenic 
and nonimmunogenic murine tumor of three distinct histological types, Cancer Res. 
1986 46, 4973-4978 
Pavletic,Z., Benyunes,M.C., Thompson,J.A., Lindgren,C.G., Massumoto,C., 
Alderson,M.R., Buckner,C.D., Fefer,A., Induction by interleukin-7 of lymphokine-
activated killer activity in lymphocytes from autulogous and syngeneic marrow 
transplant recipients before and after systemic interleukin-2 therapy.(abstract) 
Exp. Hematol. 1993 21(10) 1371-1378 
Phillips,J.H., and Lanier,L.L., Dissection of the lymphokine-activated killer 
phenomenon. Relative contribution of peripheral blood natural killer cells and T 
lymphocytes to cytolysis. J.Exp.Med. 1986 164, 814-825 
Pure,R.K., Leland,P., In vivo treatment with interferon causes augmentation of IL-2 
induced lymphokine-activated killer cells in the organs of mice. Clin.Exp. 
Immunol. (Abstract) 1991 85, 317-325 
Ramsdell,F.J., and Golub,S.H., Generation of lymphokine-activated killer cell 
activity from human thymocytes. J.Immunol. 1987 139, 1446-1453 
89 
Rannie G.H. and Donald K.J. Estimation of the migration of thoracic duct 
lymphocytes to non-lymphoid tissues. Cell Tissue Kinet 1977 10, 523-541 
Rapoport S.I., Osmotic opening of the blood-brain barrier. Ann.Neural 1988 24, 677-
684 
Rapoport,S.I., Blood-brain Barrier disruption in Brain-tumour therapy. J. Neurosurg 
1990 73, 475-476 
Ratner,S., Lymphocytes stimulated with recombinant human interleukin-2: 
relationship between motility into protein matrix and in viva localization in 
normal and neoplastic tissues of mice. J.Natl.Cancer Inst. 1990 82, 612-616 
Reynolds, C.W., Timonen,T. and Herberman R.B., Natural Killer (NK) cell activity 
in the rat I. isolation and characterization of the effector cells. J.Immunol. 1981a 
127, 282-287 
; Reynolds,C.W., Sharrow,S.O., Ortaldo,J.R., and Herberman R.B., Natural killer 
activity in the rat. II. Analysis of surface antigens on LGL by flow cytometry. 
J.Immunol. 1981b 127, 2204-2208 
Reynolds,C.W., Maghazachi,A.A., Denn IIl,A.C., Barlozzari,T., Wiltrout,R.H., 
Reichardt,D.A., and Herberman, R.B., Natural killer activity in the rat: IV. 
Distribution of large granular lymphocytes(LGL) following intravenous and 
intraperitoneal transfer. Celluar Immunol. 1984 86, 371-380 
Rodolfo,M., Salvi,C., Parmiani,G., Influence of the donors' clinical status on in vitro 
and in vivo tumor cytotoxic activation of interleukin-2-exposed lymphocytes and 
their circulation in different organs. Cancer Immunol. Immunother. 1989 28, 136-
142 
Rodolfo,M., Salvi,C., Bassi,C., and Parmiani,G., Adoptive immunotherapy of a 
mouse colon carcinoma with recombinant interleukin-2 alone or combined with 
lymphokine-activated killer cells or tumor-immune lymphocytes, Cancer Immunol 
Immunother 1990 31, 28-36 
Rolstad,B., Herberman,R.B., and Reynolds,C.W., Natural killer cell activity in 
the rat V. the circulation patterns and tissue localization of peripheral blood 
large granular lymphocytes(LGL). J.Immunol. 1986 136, 2800-2808 
Rosenberg,S.A., Grimm,E.A., McGrogan,M., et al: Biological activity of recombinant 
human interleukin-2 produced in Escherichia coll. Science 1984 223, 1412-1415 
Rosenberg,S.A., Mule,J.J., Immunotherapy of cancer with lymphokine-activated 
killer cells and recombinant interleukin-2, Surgery 1985a 6-9 437-443 
Rosenberg,S.A., Mule,J.J., Spiess,P.J., Reichert,C.M., Schwarz,S.L., Regression of 
established pulmonary metastases and subcutaneous tumor mediated by the 
systemic administration of high-dose recombinant interleukin-2 J.Exp.Med., 
1985b 151, 1169-1188 
Rosenberg,S.A., Lotze,M.T., Muul,L,M., Leitman,S., Chang,A.E., Vetto, J.T., 
Seipp,C.A., Simpson C., A new approach to the therapy of cancer based on the 
systemic administration of autologous lymphokine-activated killer cells and 
recombinant interleukin-2 Surgery 1986a 13-15 262-272 
Rosenberg, S.A., The adoptive immunotherapy of cancer using the transfer of 
activated lymphoid cells and interleukin-2, Semin Oneal. 1986b 13, 200-206 
Rosenberg,S.A., Spiess,P., Lafreniere,R., A new approach to the adoptive 
immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986c 233, 
1318-1321 
Rosenberg,S.A., Lotze,M.T., Muul,L.M., Chang,A.E., Avis,F.P., Leitman,S., Linehan, 
W.M., Robertson,C.N., Lee,R.E., Rubin, J.T., Seipp,C.A., Simpson,C.G., and 
White,D.E., A progress report on the treatment of 157 patient with advanced 
cancer using lymphokine-activated killer cells and interleukine-2 or high-dose 
interleukin-2 alone, N. Engl. J. Med. 1987 316, 889-897 
Rosenberg,S.A., Adoptive immunotherapy for cancer. Scientific American, 1990 34-
41 
Rosenstein M., Yron,I., Kaufmann,Y., and Rosenberg,S.A., Lymphokine-activated 
killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by 
lymphocytes cultured in interleukin-2 Cancer Res. 1984 44, 1946-1953 
90 
Ruscetti,F.W., Morgan,D.A., and Gallo,R., Functional and morphological 
charactrisation of human T-cell continously grown in vitro. J.Immunol, 1977 119, 
131-138 
Sacchi,M., Galeazzi,E., Johnson,J.T., Cavalot, A.L., Cortesina,G., Aii.titumor activity 
of adherent LAK cells (A-LAK)in a model of squamous carcinoma of the head and 
neck. (abstract) 1991 
Salup,R.R., and Wiltrout R.H., Adjuvant immunotherapy of established murine renal 
cancer by interleukin-2 stimulated cytotoxic lymphocytes, Cancer Res. 1986 46, 
3358-3363 
Salup,R.R., Mathieson,B.J., and Wiltrout,R.H., Precursor phenotype of lymphokine-
activated killer cells in the mouse. J.Inununol. 1987 138, 3635-3639 
Sasaki,A., Reynolds,C.W., Jain,R.K., Maghazachi,A.A., Goldfarb,R.H., and 
Herberman,R.B., Low deformability of lymphokine-activated killer cells as a 
possible determinant of in vivo distribution. Cancer Res. 1989 49, 3742-3746 
Sasaki,A., Melder,R.J., Whiteside,T.L., Herberman,R.B., Jain,R.K., Preferential 
localization of human adherent lymphokine-activated killer cells in tumor 
Microcirculation. Reports 1991 83, 433-437 
Schmidt,R.E., Murray, C., Daley, J.F., et al., A subset of Natural Killer cells in 
peripheral blood displays a mature T cell phenotype. J. Exp. Med. 1986 164, 351-
356 . 
Schoof,D.D., Gramolini,B.A., Davidson,D.L., Massaro,A.F., Wilson,R.E., 
Eberlein,T.J., Adoptive immunotherapy of human cancer using low-dose 
recombinant interleukin-2 and lymphokine-activated killer cells, Cancer Res. 
1988 48, 5007-5010 
Schoof,D.D., Terashima,Y., Batter,S., Douville,L., Richie,J.P., Eberlein,T.J., Survival 
characteristics of metastatic renal cell carcinoma patients treated with 
lymphokine-activated killer cells plus interleukin-2.(abstract) Urology 1993 
41(6) 534-539 
Schwarz,R.E., Vujanovic,N.L., and Hiserodt,J.C., Enhanced antimetastatic activity 
of lymphokine-activated killer cells purified and expanded by their adherence to 
plastic Cancer Res. 1989 49, 1441-1446 
Schwarz,R.E., and Hiserodt,J.C., Effects of splenectomy on the development of tumor-
specific immunity, J. Sur. Res. 1990 48, 448-453 
Scudeletti,M., Filaci,G., Imro,M.A., Motta,G., Di Gaetano,M., Pierri,!., Tongiani,S., 
Indiveri,F., Puppo,F., lmmunotherapy with intralesional and systemic interleukin-
2 of patients with non-small-cell lung cancer. (abstract) Cancer Inununol. 
Immunother. 1993 37(2) 119-124 
Shau,H., and Golub,S.H., Depletion of NK cells with the lysosomotropic agent L-
Leucine methyl ester and the in vitro generation of NK activity from NK precursor 
cells. J. Inununol. 1985 134, 1136-1141 
Shiraiwa,H., Sekine,T., Tobisu,K., Kakizoe,T., Koiso,K., Anew form of specific 
targeting cancer immunotherapy using anti-tumour monoclonal antibody-conjugated 
killer cells. (Abstract) 1991 
Shu,S., and Rosenberg,S.A., Adoptive immunotherapy of newly induced murine 
sarcomas, Cancer Res. 1985 45, 1657-1662 
Smith, K.A., Lachmanm,L.B., Oppenheim,J.J., and Favata,M.F., The functional 
relationship of the interleukins, J. Exp. Med., 1980 151, 1551-1556 
Strassmann,G., Bach,F.H., and Zarling,J.M., Depletion of human NK cells with 
monoclonal antibodies allows the generation of cytotoxic T lymphocytes without 
NK-like cells in mixed cultures. J. Inununol. 1983 130, 1556-1560 
Suzuki,M., et al., Sequelae of the osmotic blood-brain barrier opening in rats J. 
Neurosurg 1988 69, 421-428 
Sugo,E., and Gyory,A.Z., Acute mannitol and saline volume expansion in the rat: 
effect on transepithelial potential difference in proximal tubules. Clin. Exp. 
Pharmacol. Physiol. 1990 17, 51-59 
Takahashi,H., Nakada,T., Puisieux,I., Inhibition of human colon cancer growth by 
antibody-directed human LA.k ce~ in· SCID mice.(abstract) Science 1993 
259(5100) 1460-1463 
91 
Takai,N., Tanaka,R., Yoshida,S., Hara,N., Saito,T., Jn vivo and in vitro effect of 
adoptive immunotherapy of experimental murine brain tum.ors using lymphokine-
activated killer cells, Cancer Res. 1988 48, 2047-2052 
Talmadge,J.E., Wiltrout,R.H., Counts,D.F., Herberman,R.B., McDonald,T., and 
Ortaldo,J.R., Proliferation of human peripheral blood lymphocytes induced by 
recombinant human interleukin 2: contribution of large granular lymphocytes and T 
lymphocytes. Cellular hnmunol. 1986 102, 261-272 
Talmadge,J.E., Phillips,H., Schindler,J., Tribble,H.,and Pennington,R., Systematic 
preclinic study an the therapeutic properties of recombinant human interleukin-2 
for the treatment of metastatic disease, Cancer Res., 1987 47, 5725-5732 
Taniguchi,T., Matsui,H., Fujita,T., Takaoka,C., Kashima,N., Yoshimoto,R., 
Hamuro,J., Structure and expression of cloned cDNA for human Interleukin-2. 
Nature 1983 302, 305-310 
Teichmann,J.V., Ludwig,W.D., Thiel,E., Cytotoxicity of interleukin-2-induced 
lymphokine-activated killer(LAK) cells against human leukemia and 
augmentation of killing by interferons and tumour necrosis factor. (abstract) 
Leuk.Res. 1992 16, 287-298 
Thompson,J.A., Shulman,K.L., Benyunes,M.C., Lindgren,C.G., Collins,C., Lange, P.H., 
Bush,W.H.Jr, Benz,L.A., Fefer,A., Prolonged intravenous infusion interleukin-2 and 
lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. 
(abstract) J. Clin. Oncol. 1992 10, 960-968 
Timonen,T., Ortaldo,J.R., ·and Herberman, R.B., Characteristics of human large 
granular lymphocytes and relationship to natural killer and K cells. J.Exp.Med. 
1981 153, 569-582 
Timonen,T.T., Reynolds,C.W., Ortaldo, J.R., Herberman,R.B., Isolation of human and 
rat natual killer cells. J. hnmunol Meth. 1982 51, 269-277 
Timonen,T.T., and Pakkanen,R., Induction of large granular lymphocyte morpeology 
in human peripheral blood mononuclear cells. J. hnmunol. 1987 138, 2837-2842 
Ting,C., Yang,S.S., and Hargrove,M.E., Lymphokine-induced cytotoxicity: 
Characterization of Effectors, Precursors, and regulatory ancillary cells. Cancer 
Res. 1986. 46, 513-518 
Tjota,A., Zhang,Y.Q., Piedmonte,M.R., Lee,C.L., Adoptive immunotherapy using 
lymphokine-activated killer cells and recombinant interleukin-2 in preventing and 
treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate 
tumour. (abstract) J. Urol. 1991 146, 177-183 
Treves,A.J., Cohen,I.R., and Feldman,M., hnmunotherapy of lethal metastases by 
lymphocytes sensitized against tumor cells in vitro. J. Natl. Cancer Inst. 1975 54, 
777-780 
Triozzi,P.L., Aldrich,W.A., Rinehart,J.J., Human monocytes inhibit lymphokine-
activated killer cell expansion in vitro. (abstract) Mol Biother. 1991 3, 22-25 
Tsugita,M., Yamauchi,K., Komatsu,T., Suzuki,H., Hanyu,F., Induction and clinical 
utilization of lymphokine-activated killer cells in patients with gastrointestinal 
tract cancer. (Abstract) J. Gastroenterol Hepatol. 1990 5(2), 110-115 
Uchiyama,T., Nelson,D.L., Fleisher,T.A., Waldmann,T.A., A Monoclonal antibody 
(Anti Tac) reactive with functionally mature human T-cells II Expression of Tac 
antigen an activated Cytotoxic killer T-cells, suppressor cells and an one of two 
types of helper cells. J.hnmunol. 1981 126, 1398-1403 
Villani,F., Galimberti,M., Rizzi,M., Manzi,R., Pulmonary toxicity of recombinant 
interleukin-2 plus lymphokine-activated killer cell therapy. (abstract) Eur. 
Respir.J. 1993 6(6) 828-833 
Vujanovic,N.L., Herberman,R.B., Olszowy,M.W., Cramer,D.V., Salup,R.R., 
Reynolds,C.W., Hiserodt,J.C., Lymphokine-activated killer cells in rat: Analysis 
of progenitor and effector cell phenotype and relationship to natural killer cells. 
Cancer Res. 1988a 48, 884-890 
Vujanovic,N.L., Herberman,R.B., and Hiserodt,J.C., Lymphokine-activated killer 
cells in rats : analysis of tissue and strain distribution, ontogeny,and target 
specificity. Cancer Res. 1988b 48,. 878-883 
92 
Vujanovic,N.L., Herberman,R.B., Maghazachi,A.A., and Hiserodt,J.C., Lymphokine-
activated killer cells in rats III. A simple method for the purification of large 
granular lymphocytes and their rapid expansion and conversion into lymphokine-
activated killer cells. J.Exp.Med. 1988c 167, !5-29 · 
Wakizaka,Y., Uchino.J., Augmentation of LAK cell-accumulation in tumour tissue and 
its therapeutic effect after chemotherapy. (abstract) 1992 
Wanebo,H., Blackinton,D., Weigel,T., Turk,P., Mehta,S., Augmentation of the 
lymphokine-activated killer cell response in head and neck cancer patient by 
combination interleukin-2 and interferon-alpha. (abstract) Am. J. Surg. 1991 162, 
384-387 
Watanabe,M., Kubota,T., Kitajima,M., Hakomori,S., Synergetic effect of interleukin-
2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen 
Le(a)/Le(a) (demeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in 
adoptive immunization using SCID mice.(abstract) Cancer hnmunol. Immunother. 
1993 37(4) 245-250 
Watson,J., Continuous proliferation of murine antigenic specific helper T-lymphocytes 
in culture. J.Exp.Med. 1979 150, 1510-1519 
Weiss, G.R., Margolin,K.A., Aronson,F.R., Sznol,M., Atkins,M.B., Dutcher,J.P., 
Gaynor,E.R., Boldt,D.H., Doroshow,J.H., Bar,M.H., et al, A randomized phase II 
trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus 
lymphokine-activated killer cells for advanced renal cell carcinoma. (abstract) J. 
Clin. Oncol. 1992 10, 275-281 
Weng,X.C., Mathiot,C., Michon,J., Andreu,G., Lando,D., Fridman,W.H., Inhibition 
effect of monocytes on "lymphokine-activated killer" (LAK) cell activity. 
(abstract) Cancer Detect Prev. 1991 15, 211-215 
Weiner,L.M., Holmes,M., Adams,G.P., LaCreta,F., Watts,P., Garcia,de Palazzo I., A 
human tumour xenograft model of therapy a bispedific monoclonal antibody 
targeting c-erbB-2 and CD16. (abstract) Cancer Res. 1993 53(1) 94-100 
Wilkinson S. MD Thesis, Use of Mixed Lymphocyte Tumour Cell Culture to detect 
Tumour Antigenicity of human colon and lung carcinomas. University of N.S.W. 
1993 
Williams,A.F., Barclay,A.N., Clark,S.J., Paterson,D.J., and Willi,A.C., Similarities 
in sequences and cellular expression between rat CD2 and CD4 antigens. J.Exp. Med. 
1987 165, 368-380 
Woda,B.A., McFadden,M.L., Welsh,R.M., and Bain,K.M., Sepsrstion and isolation of 
rat natual killer (NK) cells from T cells with monoclonal antibonals. J. hnmunol. 
1984 132, 2183-2184 
Worthen,G.S., Schwab III, B., Elson,E.L., Downey,G.P., Mechanics of stimulated 
neutrophils: cell stiffening induces retention in capillaries Science 1989 245, 183-
186 
Wu,Y., Cai,D., Study of the effect of lithium on lymphokine-activated killer cell 
activity and its antitumor growth. (abstract) Proc. Soc. Exp. Biol. Med. 1992 201, 
(3) 284-288 
Yamamoto,M., Iizuka,H., Fujii,H., Matsuda,M., Miura,K., Hepatic arterial infusion 
of interleukin-2 in advanced hepatocellular carcinoma. (abstract) Acta Oncol. 
1993 32(1) 43-51 
Yamaue,H., Tanimura,H., Noguchi,K., Iwahashi,M., Tsunida,T., Tani,M., Tamai,M., 
Hatta, T., Mizobata,S., Arii,K., Cisplatin treatment renders tumour cells more 
susceptible to attack by lymphokine-activated killer cells. (abstract) J.Clic. Lab. 
hnmuno. 1991 35(4) 165-170 
Yanagawa,H., Sone,S., Fukuta,K., Nishioka,Y., Ogura,T., Local adoptive 
immunotherapy using lymphokine-activated killer cells and interleukin-2 against 
malignant pleural mesothelioma: report of two cases. (abstract) 1991 
Yang,J.C., Mule,J.J., and Rosenberg,S.A., Murine lymphokine-activated killer (LAK) 
cells; phenotypic characterization of the precursor and effector cells. J.Immunol. 
1986 137, 715-722 
93 
Yoshida,S., Tanaka,R., Takai,N., Ono,K., Local administration of autologous 
lymphokine-activated killer cells and recombinant interleukin-2 to patients with 
malignant brain tumors, Cancer Res. 1988 48, 5011-5016 
Yron,I., Wood,T.A. Spiess,P., Rosenberg,S.A., In vitro growth of murfu.e T cells: v. The 
isolation and growth of lymphoid cells infiltrating syngeneic solid tumor. J. 
Immunol 1980 125, 238-245 
Zarling,J.M., and Bach,F.H., Continuous culture of T cells cytotoxic for autologous 
human leukemia cells. Nature(Lond.) 1979 280, 685-688 
Zoller,M., Bellgrau,D., Axberg,I., and Wigzell,H., Natural Killer Cells do not belong 
to the recirculating Lymphocyte population. Scand.J.Immunol. 1982 15, 159-167 
94 
Appendix 1 Distribution of A-LAI< Cells by Systemic and 
Regional Infusion and by the Effect of Intraportal Mannitol 
After labelled the A-LAI< cells with 51Cr, lml of cells in PBS were 
infused into syngeneic male rat through tail vein or portal vein. Two 
hours later the rats were sacrificed and the organs and blood were 
taken for gamma-count to study the distribution of the A-LAI< cells in 
different organs. Table A, B and C present the records of the trafficking , 
study in these three groups. CPM is the radioactivity remained in 
infused cells in vivo 2h after infusion and it is obtained by subtracting 
SR from the total-injected-cpm. CPM of all cells =total injected cpm x 
(1-%spontaneous release). It is presumed that the released 51Cr had 
been cleaned from the blood stream through the kidneys. The 
%distribution per organ = 100 x cpm in organ I CPM. For some organs 
the radioactivity counts were obtained by counting part of these organs. 
The weights of the counted pieces and the uncounted remainder are 
recorded in Table D. 
The relevant formulae are summarised below: 
CPMof organ %distribution of LAK cells in organ= 
CPM of organ= cpm of piece of organ 
%counted 
CPM of all cells 
%distribution of LAI< cells per G= %distribution in organ 
weight of organ 
%counted= weight of counted piece xlOO 
weight of whole organ 
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Table A Distribution of A-LAK cells by tail vein infusion 
Ratl Blood Spleen Kidney MLN 1m12 Liver Brain Total 
CPM of all 2160 
cells 
cpm of 6.9/ml 10.1 9.7 0 28.9 19.0 0.8 peiceof 
organ 
cpmof 69 
organ 10.1 28.7 0 124.6 358.5 3.36 595 
o/odis-bon 3.2% per ore:an 0.5% 1.3% 0 5.8% 16.6% 0.2% 27.5% 
weight of 0.4 2.1 0.19 1.12 11.65 1.22 
organ (e:) 
%dis-bon 1.25% 0.62% per gram 0 5.18% 1.43% 0.16% 
Rat 2 Blood Spleen Kidnev MLN LUOI! Liver Brain Total 
CPM of all 9856 
cells 
cpm of 35/ml 169.1 234.4 8.5 564.2 268.5 5.3 peice of 
organ 
cpmof 350 
organ 169.l 234.4 2.8/LN 1432 1561 11.3 3970 
o/od!s-tion 
per ore:an 3.6% 1.7% 2.4% 0.07% 14.5% 15.8% 0.1% 40% 
weight of 0.49 1.18 0.04 0.66 6.56 0.96 
organ (g) 
0/od!s-bon 3.47% 2.03% 5.25% 21.9% 2.41% 0.1% per gram 
Rat 3 Blood Spleen Kidney MLN LUllg Liver Brain Total 
CPM of all 4475 
cells 
cpm of 6.9 100.6 42.8 8.5 172.5 134.9 0.3 peiceof 
ore:an 
cpmof 
ore: an 
69 100.6 42.8 2.8/LN 638.9 1226.4 2.5 2080 
%dis-tion 
per or= 1.5% 2.2% 1% 0.06% 14.3% 27.4% 0.06% 46.5% 
weight of 0.58 1.63 0.05 0.89 8.94 1.26 
organ (g) 
%dis-tion 3.79% 0.61% 3.8% 16.1% 3.07% 0.05% per gram 
Rat 4 Blood Spleen Kidney MLN 1m12 Liver Brain Total 
CPM of all 10760 
cells 
cpm of 24.8 80.0 163.8 9.4 348.6 132.6 2.0 peiceof 
ore: an 
cpmof 496 
ore:an 
80 163.8 3.1/LN 922.2 808.5 5.2 2479 
o/odis-bon 
per organ 4.6% 0.7% 1.5% 0.02% 8.6% 7.5% 0.05% 23% 
weight of 0.41 1.14 0.04 0.74 5.91 1.05 
ore:an (e:) 
o/od!s-tion 
per gram 1.71% 1.32% 2.18% 11.6% 1.27% 0.048% 
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Rat 5 Blood Spleen Kidney MLN l..un2 Liver Brain Total 
CPMof all 3519 
cells 
cpm of 13.5 13.7 50.2 4.2 64.4 17.5 0 peiceof 
orean 
cpmof 135 13.7 50.2 
orean 
1.4 213.9 157.7 0 
%chs-bon 3.8% 0.4% 1.4% 0.04% 6.1% 4.5% 0% 16.2% perorean 
weight of lml 0.54 1.31 0.1 0.83 7.51 1.26 orean (g) 
%di.s-bon 0.74% 1.07% 1.2% 7.3% 0.6% 0% per eram 
Rat 6 Blood Spleen Kidney MLN Lung Liver Brain Total 
CPM of all 8376 
cells 
cpm of 15.8 114.4 93.4 5.3 303.4 141.4 0.5 peiceof 
orean 
cpmof 
organ 158 114.4 93.4 1.8 1465.7 1536.9 1.64 3401.8 
o/odt.s-bon 
perorean 1.9% 1.4% 1.1% 0.02% 17.5% 18.4% 0.02% 40.3% 
weight of 0.45 1.45 0.09 0.92 8.06 1.31 organ (g) 
0/odt.s-bon 3.1% 0.76% 0.7% 19% 2.3% 0.015% per eram 
Rat 7 Blood Spleen Kidney MLN Lung Liver Brain Total 
CPMof all 12143 
cells 
cpm of 17.5 129.3 138 8.3 438.2 125 3.8 peiceof 
organ 
cpmof 
organ 175 129.3 138 2.8 2047.7 477.1 10.8 
o/odt.s-bon 1.4% 1.1% 1.1% 0.02% 16.9% 3.9% 0.09% 24.5% perorean 
weight of 0.58 1.45 0.04 0.84 9.5 1.22 
orean (g) 
%dis-bon 
per eram 1.9% 0.76% 1.7% 20% 0.41% 0.07% 
Rat 8 Blood Spleen Kidney MLN l..un2 Liver Brain Total 
CPM of all 8226 
cells 
cpm of 6.9 336.7 228.6 14.7 929.6 278.1 8.1 peiceof 
orean 
cpmof 138 336.7 228.6 4.9 3417.6 3056 34.6 7225 organ 
o/odt.s-bon 
per organ 1.7% 4.1% 2.8% 0.06% 41.5% 37.2% 0.42% 87.8% 
weight of 0.66 1.23 0.06 0.81 6.5 1.28 organ (g) 
%chs-tion 6.2% 2.3% 2.9% 51% 5.72% 0.33% per eram 
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Table B Distribution of A-LAK cells by portal vein infusion 
Rat 1 Blood Spleen Kidney MLN Lung Liver Brain Total 
CPM of all 4153 
cells 
cpm of 10.9 14.8 42 7.8 80.5 92.2 0 peiceof 
organ 
cpmof 121.1 14.8 42 
organ 2.6/LN 281.5 434.9 0 896.9 
%dis-lion 2.9% per or= 0.4% 1% 0.06% 6.8% 10.5% 0 21.6% 
weight of 0.43 1.05 0.03 0.63 4.72 1.03 organ (g) 
'l'oehs-t10n 0.93% 0.95% 6.26% 10.8% 2.25% 0 per gram 
Rat 2 Blood Spleen Kidney MLN Lung Liver Brain Total 
CPM of all 8424 
cells 
cpm of 9.0 138.5 114.5 0 364.9 153.0 0.5 peice of 
organ 
cpmof 
organ 900 138.5 602.6 0 1658.6 1700 2.5 5001 
%dis-lion 10.7% 1.6% 7.2% 0 19.7% 20.2% 0.03% 59.4% per organ 
weight of 0.37 2.16 0.13 1.62 9.75 1.66 
organ(!!:) 
0/oehs-bon 
per gram 4.32% 3.33% 0 12.2% 2.07% 0.02% 
Rat 3 Blood Spleen Kidney MLN Lung Liver Brain Total 
CPM of all 7007 
cells 
cpm of 5.6 48.3 19.7 0 50.0 103.3 0 peice of 
organ 
cpmof 140 48.3 48.9 
organ 0 284.1 1122.8 0 1644.1 
%dis-bon 2% 0.7% 0.7% 0 0.3% 16% 0 23.5% per organ 
weight of 0.48 1.34 0.15 0.91 7.59 1.48 
organ (g) 
'l'oehs-bon 1.46% 0.52% per gram 0 0.33% 2.11% 0 
Rat 4 Blood Spleen Kidney MLN Lune; Liver Brain Total 
CPM of all 23787 
cells 
cpm of 11.2 63.0 122.6 16.9 194.4 1236.9 5.5 peke of 
orl!'.an 
cpmof 
organ 280 63 123 5.6/LN 627 8530 13 9641.6 
0/oehs-bon 
per organ 1.2% 0.3% 0.5% 0.02% 2.6% 36% 0.06% 40.5% 
weight of 0.44 1.25 0.08 0.81 6.13 0.96 
organ (g) 
%dLS-bon 0.68% 0.4% per gram 0.89% 3.21% 5.87% 0.06% 
98 
Rat 5 Blood Spleen Kidney MLN LUl12 Liver Brain Total 
CPMofall 7718 
cells 
cpm of 16.3 37.9 82.8 4.8 35.6 150.2 6.3 peiceof 
organ 
cpmof 
organ 163 37.9 82.8 1.6 126.4 1314.1 23.4 
o/odis-tion 2.1% 0.5% 1.1% 0.02% 1.6% 17% 0.3% 22.6% per orl?an 
weight of 0.51 1.42 0.04 0.71 8.05 1.3 organ (g) 
o/odis-bon 0.98% 0.77% oer gram 1.6% 2.29% 2.1% 0.23% 
Rat 6 Blood Spleen Kidney MLN LUl12 Liver Brain Total 
CPMof all 12134 
cells -
cpm of 25.4 104.9 82.4 6.6 122.2 283.1 0 peiceof 
organ 
cpmof 
organ 254 104.9 82.4 2.2 558 3217 0 
%dis-bon 
per organ 2.1% 0.9% 0.7% 0.02% 4.6% 26.5% 0 34.8% 
weight of 0.4 1.43 0.05 0.73 7.7 1.15 
organ (g) 
%dis-tion 
per gram 2.25% 0.49% 1.1% 6.3% 3.44% 0 
Rat 7 Blood Spleen Kidney MLN LUl12 Liver Brain Total 
CPMof all 8226 
cells 
cpm of 26.2 224.9 170.2 7 143.3 387.4 4.8 peiceof 
organ 
cpmof 524 224.9 170.2 2.3 612.4 3761.2 17.45 
organ 
%dJS-tion 6.3% 2.7% 2.1% 0.03% 7.4% 45.7% 0.2% 57.0% 
oer orvan 
weight of 0.45 0.96 0.04 ' 0.64 4.95 1.2 
organ (g) 
%dJS-tion 6% 2.19% 2.1% 11.6% 9.2% 0.17% 
oer gram 
Rat 8 Blood Spleen Kidney MLN LUl12 Liver Brain Total 
CPMofall 8226 
cells 
cpm of 5.0 54.7 78.4 7 19.9 207.9 1.0 peiceof 
organ 
cpmof 166.7 organ 54.7 78.4 2.3 108.2 1856.3 2.87 
%dis-bon 
per organ 2% 0.7% 0.95% 0.03% 1.3% 23% 0.03% 28.0% 
weight of 0.59 1.09 0.05 0.76 5.78 1.09 
organ (g) 
%dis-bon 1.19% 0.87% 1.7% 1.7% 3.98% 0.03% 
oer gram 
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Table C Distribution of A-LAI< cells by the effect of intraportal 
mannitol 
Rat 1 Blood Spleen Kidney MLN Lung Liver Brain 
CPMof all 
cells 
cpm of 19.2 40.7 123.2 5.9 209.3 405.4 2.3 peiceof 
or!!an 
cpmof 192 or!!an 40.7 123.2 1.97 550.8 3898 8.7 
%dis-tion 1.6% 0.3% 0.5% 0.02% 4.5% 32% 0.07% per organ 
weight of 0.46 1.22 0.04 0.74 6.83 1.1 organ (g) 
%dis-tion 0.65% 0.41% 1.21% 6.08% 4.69% 0.064% per !!:ram 
Rat2 Blood Spleen Kidney MLN Lung Liver Brain 
CPMof all 
cells 
cpm of 45.4 76.6 132.8 9.8 300.9 513.2 4.0 peiceof 
organ 
cpmof 454 
organ 76.6 132.8 3.3 999.7 3539.3 14.3 
%dis-bon 
per organ 5.9% 1% 1.7% 0.04% 13.2% 46.4% 0.2% 
weight of 0.37 1.06 0.03 0.73 5.39 1.5 
organ(!!) 
%dis-tion 2.7% 1.6% 4.3% 18.1% 8.65% 0.13% per gram 
Rat 3 Blood Spleen Kidney MLN Lung Liver Brain 
CPM of all 
cells 
cpm of 65.3 50.3 197.8 11.9 302.6 634.7 3.5 peiceof 
organ 
cpmof 
or!!an 653 50.3 197.8 3.9 829 3800.6 7.7 
%dis-bon 
per organ 9.3% 0.7% 2.8% 0.05% 11.8% 54% 0.01% 
weight of 0.44 0.99 0.04 0.74 4.56 0.95 
organ (g) 
%dJS-bon 
per gram 1.59% 2.83% 4.23% 16% 11.84% 0.01% 
Rat4 Blood Spleen Kidney MLN Lung Liver Brain 
CPMof all 
cells 
cpm of 19.2 363.1 241.4 14.3 369.9 745 4.0 peiceof 
organ 
cpmof 
or!!an 192 363.1 241.4 4.7 1185.6 6478.3 9.5 
%dls-bon 1.8% per organ 3.4% 2.3% 0.04% 11% 60% 0.09% 
weight of 0.4 1.17 0.04 0.77 6.33 1 
or!!an (!!) 
%dis-bon 
per gram 8.5% 1.97% 3.32% 14.3% 9.48% 0.09% 
100 
Total 
12210 
4815.2 
39.4% 
Total 
7589 
5220 
68.8% 
Total 
7038 
5535 
78.6% 
Total 
10760 
8474.6 
78.8% 
Rat 5 Blood Spleen Kidney MLN Lung Liver Brain Total 
CPMof all 
cells 
3519 
cpm of 10.9 16.3 48.6 6.8 52.6 296.8 3.3 peiceof 
organ 
cpmof 
organ 109 16.3 48.6 2.27 189.2 2650 11.7 
'Yodis-lion 3.1% 0.5% 1.4% 0.06% 5.4% 75.3% 0.3% 86.1% per organ 
weight of 0.5 1.19 0.08 0.72 5.99 1.25 ore:an (g) 
%chs-tion 1% 1.18% 2.42% 7.5% 12.6% 0.24% per e:ram 
Rat 6 Blood Spleen Kidney MLN Lung Liver Brain Total 
CPMof all 6407 
cells 
cpm of 19.4 78.9 92.2 24.2 147.6 4474.4 5.9 peiceof 
organ 
cpmof 
organ 194 78.9 92.2 8.1 833.9 4474.4 24.9 
%clis-non 3.0% 1.2% 1.4% per ore:an 0.1% 13% 69.8% 0.39% 88.9% 
weight of 0.45 1.12 0.06 0.79 5.99 1.39 organ (g) 
%chs-non 
per gram 2.7% 1.25% 6.3% 16.5% 11.7% 0.28% 
Rat 7 Blood Spleen Kidney MLN Lung Liver Brain Total 
CPMof all 6407 
cells 
cpm of 26.9 24.1 45.2 4.8 72.3 3316.3 10.9 peiceof 
organ 
cpmof 
organ 269 24.1 45.2 1.6 361.5 3316.3 41.3 
%dis-lion 
per organ 4.2% 0.38% 0.7% 0.03% 5.6% 51.8% 0.65% 63.4% 
weight of 0.4 1.1 0.06 0.7 5.93 1.4 
organ (g) 
%chs-tion 
per e:ram 0.95% 0.64% 1.25% 8% 8.7% 0.46% 
Rats Blood Spleen Kidney MLN Lune; Liver Brain Total 
CPM of all 6147 
cells 
cpm of 7.1 31.8 43 8.1 162.3 2634.5 24.5 peiceof 
organ 
cpmof 
organ 71 31.8 43 2.7 162.3 2634.5 24.5 
%dis-non 
per organ 1.2% 0.5% 0.7% 0.04% 2.64% 42.9% 0.4% 48.4% 
weight of 0.41 1.29 0.05 0.81 6.09 1.47 organ (g) 
%dis-non 
per e:ram 1.22% 0.54% 2.7% 3.26% 7.04% 0.27% 
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a e . ht rgan we1g. d recor s 
Group 1 Weight of peke Weight of left Weight of organ %Counted 
Ratl of organ organ (g) 
counted(g) un-counted(I?) 
Blood lml 9ml 10% 
Spleen 0.4 0.4 100% 
Kidney 0.71 1.39 2.1 33.8% 
MLN 0.19 0.19 100% 
Lung 0.26 0.86 1.12 23.2% 
Liver 0.62 11.03 11.65 5.3% 
Brain 0.29 0.93 1.22 23.8% 
Group 1 Weight of peke Weight of left Weight of organ %Counted 
Rat2 of organ organ (g) 
counted(g) un-counted(g) 
Blood lml 9ml 10% 
Spleen 0.49 0.49 100% 
Kidney 0.59 1.18 100% 
0.59 
MLN 0.04 0.04 
Lung 0.26 0.4 0.66 39.4% 
Liver 1.13 5.43 6.56 17.2% 
Brain 0.45 0.51 0.96 46.9% 
Group 1 Weight of peke Weight of left Weight of organ %Counted 
Rat3 of organ organ (g) 
counted(g) un-counted(I?) 
Blood lml 10ml 10% 
Spleen 0.58 0.58 100% 
Kidney 0.8 1.63 100% 
... 0.83 
MLN 0.05 0.05 
Lung 0.24 0.65 0.89 27% 
Liver 0.98 7.96 8.94 11% 
Brain 0.15 1.11 1.26 12% 
Group 1 Weight of peke Weight of left Weight of organ %Counted 
Rat4 of organ organ (g) 
counted(g) un-counted(g) 
Blood 0.5ml 10ml 5% 
Spleen 0.41 0.41 100% 
Kidney 0.57x2 1.14 100% 
MLN 0.04 0.04 
Lung 0.28 0.46 0.74 37.8% 
Liver 0.97 4.94 5.91 16.4% 
Brain 0.4 0.65 1.05 38.1% 
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Group 1 Weight of peice Weight of left Weight of organ %Counted 
Rats of organ organ (g) 
counted(g) un-counted(g) 
Blood lml 10ml 10% 
Spleen 0.54 0.54 100% 
Kidney 0.66 1.31 100% 
0.65 
MLN 0.1 0.1 
Lung 0.25 0.58 0.83 30.1% 
Liver 0.83 6.68 7.51 11.1% 
Brain 0.34 0.92 1.26 26.9% 
Group 1 Weight of peice Weight of left Weight of organ %Counted 
Rat6 of organ organ (g) 
counted(g) un-counted~ 
Blood lml 10ml 10% 
Spleen 0.45 0.45 100% 
Kidney 0.7 1.45 100% 
0.75 
MLN 0.09 
Lung 0.19 0.73 0.92 20.7% 
Liver 0.74 7.32 8.06 9.2% 
Brain 0.4 0.91 1.31 30.5% 
Group 1 Weight of peice Weight of left Weight of organ %Counted 
Rat 7 of organ organ (g) 
counted(g) un-counted(g) 
Blood lml 10ml 10% 
Spleen 0.58 0.58 100% 
Kidney 0.69 1.45 100% 
0.76 
MLN 0.04 
Lung 0.18 0.66 0.84 21.4% 
Liver 2.49 7.01 9.5 26.2% 
Brain 0.43 0.79 1.22 35.3% 
Group 1 Weight of_ peice Weight of left Weight of organ %Counted 
Rats of organ organ (g) 
counted(g) un-counted(W 
Blood 0.5ml 10ml 5% 
Spleen 0.66 0.66 100% 
Kidney 0.6 1.23 100% 
0.63 
MLN 0.06 
Lung 0.22 0.59 0.81 27.2% 
Liver 0.59 5.91 6.5 9.1% 
Brain 0.3 0.98 1.28 23.4% 
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Group2 Weight of peice Weight of left Weight of organ %Counted 
Ratl of organ organ (g) 
counted(g) un-counted(g) 
Blood 0.9ml lOml 9% 
Spleen 0.43 0.43 100% 
Kidney 0.55 1.05 100% 
0.5 
MLN 0.03 0.03 
Lung 0.18 0.45 0.63 28.6% 
Liver 1 3.72 4.72 21.2% 
Brain 0.42 0.61 1.03 40.8% 
Group 2 Weight of peice Weight of left Weight of organ %Counted 
Rat2 of organ organ (g) 
counted(g) un-counted(g) 
Blood 0.lml lOml 1% 
Spleen 0.37 0.37 
Kidney 0.41 1.75 2.16 19% 
MLN 0.13 0.13 
Lung 0.36 1.26 1.62 22% 
Liver 1.41 8.34 9.75 9% 
Brain 0.34 1.32 1.66 20% 
Group 2 Weight of peice Weight of left Weight of organ %Counted 
Rat3 of organ organ (g) 
counted(g) un-counted(e:) 
Blood 0.4ml lOml 4% 
Spleen 0.48 0.48 100% 
Kidney 0.54 0.8 1.34 40.3% 
MLN 0.15 0.15 
Lung 0.16 0.75 0.91 17.6% 
Liver 0.7 6.89 7.59 9.2% 
Brain 0.45 1.03 1.48 30.4% 
Group 2 Weight of peice Weight of left Weight of organ %Counted 
Rat4 of organ organ (g) 
counted(g) un-counted(e:) 
Blood 0.3ml lOml 3% 
Spleen 0.44 0.44 100% 
Kidney 0.59 1.25 100% 
0.66 
MLN 0.08 0.08 
Lung 0.25 0.56 0.81 31% 
Liver 0.89 5.24 6.13 14.5% 
Brain 0.4 0.56 0.96 42% 
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Group 2 Weight of peke Weight of left Weight of organ %Counted 
Rats of organ organ (g) 
counted(g) un-counted~ 
Blood lml lOml 10% 
Spleen 0.51 0.51 100% 
Kidney 0.69 1.42 100% 
0.73 
MLN 0.04 
Lung 0.2 0.51 0.71 28.2% 
Liver 0.92 7.13 8.05 11.43% 
Brain 0.35 0.95 1.3 26.9% 
Group 2 Weight of peke Weight of left Weight of organ %Counted 
Rat 6 of organ organ (g) 
counted(g) un-counted(g) 
Blood lml lOml 10% 
Spleen 0.4 0.4 100% 
Kidney 0.7 1.43 100% 
0.73 
MLN 0.05 
Lung 0.16 0.57 0.73 21.9% 
Liver 0.68 7.02 7.7 8.8% 
Brain 0.43 0.72 1.15 37.4% 
Group 2 Weight of peke Weight of left Weight of organ %Counted 
Rat7 of organ organ (g) 
counted(g) un-counted(g) 
Blood 0.5ml lOml 5% 
Spleen 0.45 0.45 100% 
Kidney 0.47 0.96 100% 
0.49 
MLN 0.04 
Lung 0.15 0.49 0.64 23.4% 
Liver 0.51 4.44 4.95 10.3% 
Brain 0.33 0.87 1.2 27.5% 
Group 2 Weight of peke Weight of left Weight of organ %Counted 
Rats of organ organ (g) 
counted(g) un-countedfa) 
Blood 0.3ml lOml 3% 
Spleen 0.59 0.59 100% 
Kidney 0.53 1.09 100% 
0.56 
MLN 0.05 
Lung 0.14 0.62 0.76 18.4% 
Liver 0.65 5.13 5.78 11.2% 
Brain 0.38 0.71 1.09 34.9% 
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Group 3 Weight of peice Weight of left Weight of organ %Counted 
Ratl of organ organ (g) 
counted(g) un-countedW 
Blood lml lOml 10% 
Spleen 0.46 0.46 100% 
Kidney 0.6 1.22 100% 
0.62 
MLN 0.04 0.04 
Lung 0.28 0.46 0.74 38% 
Liver 0.71 6.12 6.83 10.4% 
Brain 0.29 0.81 1.1 26.4% 
Group 3 Weight of peice Weight of left Weight of organ %Counted 
Rat2 of organ organ (g) 
counted(g) un-counted(g) 
Blood lml lOml 10% 
Spleen 0.37 0.37 100% 
Kidney 0.54 1.06 100% 
0.52 
MLN 0.03 0.03 
Lung 0.22 0.51 0.73 30.1% 
Liver 0.78 4.61 5.39 14.5% 
Brain 0.42 1.08 1.5 28% 
Group 3 Weight of peice Weight of left Weight of organ %Counted 
Rat3 of organ organ (g) 
counted(g) un-counted(g) 
Blood lml lOml 10% 
Spleen 0.44 0.44 100% 
Kidney 0.49 0.99 100% 
0.5 
MLN 0.04 0.04 
Lung 0.27 0.47 0.74 36.5% 
Liver 0.76 3.8 4.56 16.7% 
Brain 0.43 0.52 0.95 45.3% 
Group 3 Weight of peice Weight of left Weight of organ %Counted 
Rat4 of organ organ (g) 
counted(g) un-counted(g) 
Blood lml lOml 10% 
Spleen 0.4 0.4 100% 
Kidney 0.57 1.17 100% 
0.6 
MLN 0.04 0.04 
Lung 0.24 0.53 0.77 31.2% 
Liver 0.73 5.6 6.33 11.5% 
Brain 0.42 0.58 1 42% 
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Group 3 Weight of peice Weight of left Weight of organ %Counted 
Rat 5 of organ organ (g) 
counted(g) un-counted(e:) 
Blood lml 10ml 10% 
Spleen 0.5 0.5 100% 
Kidney 1.19 1.19 100% 
MLN 0.08 
Lung 0.2 0.52 0.72 27.8% 
Liver 0.67 5.32 5.99 11.2% 
Brain 0.36 0.89 1.25 28.8% 
Group 3 Weight of peice Weight of left Weight of organ %Counted 
Rat 6 of organ organ (g) 
counted(g) un-counted(g) 
Blood lml 10ml % 
Spleen 0.45 0.45 100% 
Kidney 0.55 1.12 100% 
0.57 
MLN 0.06 
Lung 0.14 0.65 0.79 17.7% 
Liver 0.77 5.22 5.99 100% 
Brain 0.33 1.06 1.39 23.7% 
Group 3 Weight of peice Weight of left Weight of organ %Counted 
Rat 7 of organ organ (g) 
counted(g) un-counted(g) 
Blood lml lOml 10% 
Spleen 0.4 0.4 100% 
Kidney 0.54 1.1 100% 
0.56 
MLN 0.06 
Lung 0.14 0.56 0.7 20% 
Liver 0.81 5.12 5.93 100% 
Brain 0.37 1.03 1.4 26.4% 
Group 3 Weight of peice Weight of left Weight of organ %Counted 
Rats of organ organ (g) 
counted(g) un-counted(g) 
Blood lml 10ml 10% 
Spleen 0.41 0.41 100% 
Kidney 0.64 1.29 100% 
0.65 
MLN 0.05 0.05 
Lung 0.22 0.59 0.81 100% 
Liver 0.81 5.28 6.09 100% 
Brain 0.54 0.93 1.47 100% 
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Table E summarises the distribution of A-LAI< cells in organs in the 
three groups of rats. The number and viabilities of inf:used cells are 
shown in this table. The distribution results are obtained after 
calculation as shown in Table A-C. 
Table E A-LAI< cell Distribution in Three Groups of Rats 
Cells106 Viabilit SR% Blood Spleen 
y 
Kidney MLN Lung Liver Brain 
Groupl 
0.66 30% 36.9 3.2% 0.5% 1.3% 0 5.8% 16.6% 0.2% 
2.64 94% 56 3.6 1.7% 2.4% 0.1% 14.5% 15.8% 0.1% 
2.1 97% 8.6 1.5% 2.2% 1.0% 0.1% 14.3% 27.4% 0.1% 
1.5 92% 42 4.6% 0.7% 1.5% 0.02% 8.6% 7.5% 0.1% 
1.7 92% 14.5 3.8% 0.4% 1.4% 0.04% 6.1% 4.5% 0 
1.65 90% 16 1.9% 1.4% 1.1% 0.02% 17.5% 18.4% 0.02% 
1.5 85% 10.7 1.4% 1.1% 1.1% 0.02% 16.9% 3.9% 0.1% 
2.5 95% 45 1.7% 4.1% 2.8% 0.1% 41.5% 37.2% 0.4% 
Group2 
0.85 95% 43.6 2.9% 0.4% 1.0% 0.1% 6.8% 10.5% 0 
3.5 74% 55 10.7% 1.6% 7.2% 0 19.7% 20.2% 0.03% 
2.8 78% 18.9 2.0% 0.7% 0.7% 0 4.1% 16.0% 0 
1.6 71% 17.2 1.2% 0.3% 0.5% 0.02% 2.6% 36.0% 0.06% 
1 90% 28.5 2.1% 0.5% 1.1% 0.02% 1.6% 17.0% 0.3% 
1.5 85% 10.7 2.1% 0.9% 0.7% 0.02% 4.6% 26.5% 0 
2.5 95% 45 6.3% 2.7% 2.1% 0.03% 7.4% 45.7% 0.2% 
2.5 95% 45 2.0% 0.7% 0.9% 0.03% 1.3% 23.0% 0.03% 
Group3 
1.02 90% 29 1.6% 0.3% 0.5% 0.02% 4.5% 32% 0.1% 
2.86 90% 56 5.9% 1.0% 1.7% 0.04% 13.2% 46.6% 0.2% 
1.44 94% 35 9.3% 0.7% 2.8% 0.1% 11.8% 54.0% 0.01% 
1.5 92% 42 1.8% 3.4% 2.3% 0.04% 11.0% 60.0% 0.1% 
1.7 92% 14.5 3.1% 0.5% 1.4% 0.1% 5.4% 75.3% 0.3% 
2.9 92% 25.6 3.0% 1.2% 1.4% 0.1% 13.0% 69.8% 0.4% 
2.9 92% 25.6 4.2% 0.4% 0.7% 0.02% 5.6% 51.8% 0.6% 
1.6 95% 18.6 1.2% 0.5% 0.7% 0.04% 2.6% 42.9% 0.4% 
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